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Despite the most advanced therapeutic regimen, median survival of malignant gliomas remains 
~ 14 months. Given the aggressive and infiltrative nature of it, inability of conventional gene 
vectors and drug carriers to provide a widespread therapeutic distribution is an utmost 
challenge. Convection enhanced delivery (CED) is an attractive method to bypass the blood-
brain barrier and facilitate widespread therapeutic distribution within brain parenchyma by 
creating a continuous pressure-driven bulk flow. In this work I demonstrate that local infusion of 
nanoparticle (NP)-based delivery systems designed to efficiently penetrate the highly adhesive 
and nanoporous extracellular matrix synergistically enhances the payload distribution within 
healthy and tumor-bearing brains. I start by establishing in Chapter 1 the broad picture that 
medicine challenges faced with the current treatment strategies for central nervous system 
diseases, as well as the numerous barriers that NPs must overcome to successfully achieve a 
therapeutic distribution in the brain. It also describes a very detailed protocol for local infusion 
doing stereotaxic surgeries in rodent brains via CED. In Chapter 2, I established a new system 
to assess for gene transfection efficiency in vitro by utilizing 3D multicellular tumor spheroids, 
providing insights for the effect of non-adhesive coating, made of polyethylene glycol (PEG), in 
synthetic gene vectors, made of polyethyleneimine (PEI), and their extent of penetration with 
accurate in vitro-to-in vivo correlation in the brain. Furthermore, I developed a mathematical 
protocol to quantify the penetration profile of nanoparticles in the 3D multicellular tumor 
spheroids. With this model, I confirmed that NPs with higher ratios of PEG possessed better 
penetration capabilities, which led to greater volumes of transgene expression in healthy and 
tumor rat brain tissues. Using this DNA-NP system, I also demonstrated that long-term gene 
expression can be achieved in the brain up to 3 weeks, by replacing the promoter that regulates 
the expression of the reporter gene. This application may be beneficial for future therapeutic 
studies, including neurodegenerative diseases.  In Chapter 3, I demonstrated that a series of 
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eight end-capped polymer variants, made of biodegradable poly-beta-amino-ester (PBAE), 
perform differently in a mouse glioblastoma 3D model and in vivo, depending on their 
physicochemical properties and colloidal stability. I identified 4 lead candidates for widespread 
transgene expression in the brain. Furthermore, I tested the top candidate in 1 mouse 
glioblastoma model and 2 pediatric brain tumor models, which showed well transfected regions 
at the tumor site and tumor periphery. Lastly, I developed a protocol that allows freeze-drying of 
these biodegradable NPs for long-term storage as a powder form. This form of proper storing 
and cryoprotection for extended periods of time did not compromised the NPs performance in 
vivo, which serves of big relevance to our collaborators and future clinical studies. Lastly, I 
completed this work with Chapter 4, describing the effect of 3 different triblock copolymers 
consisting of a central hydrophobic block of polypropylene oxide (PPO) flanked by two 
hydrophilic blocks of polyethylene oxide (PEO) that serve as non-adhesive coatings in 
biodegradable polymer-based nanoparticles made of the hydrophobic poly(lactic-co-glycolic 
acid) (PLGA) for local drug delivery to the brain. I demonstrated that these triblock copolymers 
coat PLGA-NPs in a unique manner, depending on the content of the PPO hydrophobic block, 
resulting in better shielding of the hydrophobic core for the copolymer with the highest PPO 
ratio. Therefore, this trend showed a direct correlation between the coating efficiency of each 
copolymer and the volume of distribution in rat brain after local infusion.  Furthermore, I 
discovered that the brain intercellular space can be penetrable by nanoparticles up to ~200 nm 
in diameter when coated with the copolymer possessing the highest PPO content. Lastly, I also 
established a protocol to freeze-dry and store these particles as a powder form for long-term 
periods of time, and by increasing the osmotic pressure of the nanoparticles solution, I 
discovered that the widespread distribution can be further enhanced in the brain. This serves of 
great utility for future drug delivery studies where greater tissue coverage is necessary to kill the 
infiltrative brain cancer cells. Ultimately, I hope that this work will contribute to the greater 
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understanding of localized nanomedicine, which will help yield more effective treatments thus 
improving and extending patients’ lives. 
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Brain tumors and current status of therapeutics for malignant gliomas 
1. Brain tumors 
Brain tumors grow as an abnormal mass of tissue in which cells grow and multiply 
uncontrollably, seemingly unchecked by the molecular mechanisms that control normal cells. 
More than 150 different brain tumors have been documented, but the two main groups of brain 
tumors are termed primary and metastatic (1). Primary brain tumors include tumors that 
originate from the tissues of the brain or its surroundings. These are categorized as glial 
(derived from glial cells) or non-glial (developed on or in the structures of the brain, including 
nerves, blood vessels and glands), each type can be benign or malignant. Metastatic brain 
tumors include tumors that arise elsewhere in the body, primarily the breast or lungs, and 
migrate to the brain, usually through the bloodstream. These are considered as only malignant 
(Figure 1). 
  
Metastatic tumors affect nearly one in four patients with cancer, or an estimated 150,000 
people a year, with up to 40 percent developed from lung cancer. For the purpose of this 





elsewhere in the body
Figure 1: Schematic representation of the different types of brain tumors. Brain tumors may grow from 
nerves (neuroma), dura (meningioma), or pituitary gland (craniopharyngioma or pituitary adenoma). 
They may also grow from the brain tissue itself (glioma).  
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The estimated average mortality rate for primary brain tumors in 2018 and 2019 in the 
United States is ~18,000 deaths (2). Furthermore, 78,980 new cases are expected to be 
diagnosed this year, including malignant, non-malignant, and other types of central nervous 
system (CNS) related tumors (2). Based on population-based database analyses, the five-year 
relative survival rate in the United States following a diagnosis of a primary malignant brain and 
other CNS tumors is only 34.9% (2). Over the years, the World Health Organization (WHO) has 
developed a grading system to indicate a tumor's malignancy or benignity based on its 
histological features under a microscope (Figure 2) (3).
 
2. Currently approved therapies for brain tumors and their limitations 
Brain tumors (whether primary or metastatic, benign or malignant) usually are treated with 
surgery, radiation, and/or chemotherapy (alone or in various combinations) (Figure 3). 
Treatment for a brain tumor depends on the type, size and location of the tumor, as well as the 
patient’s overall health and preferences. 

















































Most brain tumors in infants, children, and adults require surgical removal, or at least a 
biopsy, as part of the treatment. For low-grade or slow-growing tumors, surgery may be the only 
intervention necessary. If the brain tumor is in a place that makes it accessible for an operation, 
it will be preferred to remove as much of the brain tumor as possible. This may also help to 
relieve intracranial pressure caused by the tumor, reducing signs and symptoms. However, 
surgery carries risks, such as infection and bleeding. Other risks may depend on the part of your 
brain where the tumor is located. For instance, surgery on a tumor near nerves that connect to 
the eyes may carry a risk of vision loss. Thanks to the evolution of medicine, neurosurgeons can 
now execute awake brain surgery. The procedure, offered at very few medical centers in the 
   Tumor resection                  Radiotherapy                 Chemotherapy 
Figure 3: Surgery is the treatment of choice for brain tumors that can be reached without causing 
major injury to vital parts of the brain. A neurosurgeon performs a craniotomy to open the skull and 
remove the tumor. Sometimes only part of the tumor is removed if it is near critical areas of the brain. 
Radiation or chemotherapy may be used on the remaining tumor cells. Radiation damages the DNA 
inside cells, making them unable to divide and grow. The radiation beams are shaped to match the 
tumor and minimize exposure to normal brain tissue. The benefits of radiation are not immediate but 
occur with time. Aggressive tumors, whose cells divide rapidly, tend to respond quickly to radiation. 
Over time, the abnormal cells die, and the tumor may shrink. Chemotherapy for high-grade gliomas is 
usually taken as a pill daily for a set period of time called a cycle. The drug circulates through the 
bloodstream to the brain where it crosses the blood-brain-barrier to the tumor. 
4 
 
country, is used to help certain people who've been told they have an inoperable brain tumor. 
The surgical team can remove the tumor safely with minimized risk of serious complications. 
Radiation 
Radiation therapy is performed after surgery for some types of gliomas or for those in 
locations where surgery is not safe. This is executed by using high-energy beams, such as X-
rays or protons, to kill tumor cells. Three types of radiation therapy are used to treat gliomas: 
external beam radiation therapy, internal radiation, and stereotactic radiosurgery. External beam 
radiation can focus just on the area of your brain where the tumor is located, or it can be applied 
to your entire brain (whole-brain radiation). Whole-brain radiation is most often used to treat 
cancer that spreads to the brain from some other part of the body. Stereotactic radiosurgery 
uses multiple beams of radiation to give a highly focused form of radiation treatment in a very 
small area. Each beam of radiation possesses a low power intensity, but the point where all the 
beams meet, i.e. tumor site, receives a very large dose of radiation to kill the cancer cells. This 
has been explored using new technologies such as a gamma knife or the linear accelerator. 
Common side effects during or immediately following radiation include fatigue, headaches, 
memory loss and scalp irritation. For tumors that are very close to sensitive areas of the brain, 
proton therapy may reduce the risk of side effects associated with radiation. But proton therapy 
has not proved to be more effective than standard radiation therapy with X-rays. 
Chemotherapy: Temozolomide 
Chemotherapy is used for most aggressive high-grade brain tumors. These can be 
administered orally, intravenously, injected directly into the cerebrospinal fluid, or injected 
directly into the cavity left after surgical removal of a brain tumor. The standard of care for newly 
diagnosed brain tumors, particularly glioblastoma multiforme (GBM), includes maximal safe 
tumor resection, 6 weeks of concurrent radiation with temozolomide (TMZ) as a pill, followed by 
maintenance (or adjuvant) TMZ for a total of 6 to 12 cycles (4). TMZ has increased the median 
overall survival for GBM patients from less than 12 months (5), to 14.6 months, and the 
5 
 
percentage of patients alive at two years has been reported to increase from 10.4% to 26.5% (4, 
6). However, TMZ is an alkylating agent, therefore, its therapeutic benefit depends on its ability 
to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions of guanine 
residues, triggering apoptosis (6, 7). The problem is that some tumor cells can repair this type of 
DNA damage by expressing a protein, O6-alkylguanine-DNA alkyltransferase (AGT), encoded 
in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene, thus, diminishing 
the therapeutic efficacy of TMZ (8). Furthermore, cells lacking a “normal” DNA mismatch repair 
system do not detect alkylation adducts and hence are resistant to TMZ even when they lack 
MGMT (9). Lastly, besides the drug-resistance, the major disadvantage of TMZ is its short half-
life of 1.8 h (6), thus, requiring multiple high doses for the patient.  
Targeted drug therapy: Bevacizumab 
Since angiogenesis (the growth of new blood vessels) is one of the hallmarks for most 
malignant gliomas, inhibitors of this pathway have also been approved for GBM (10). 
Bevacizumab (BEV), a humanized monoclonal antibody binding specifically to circulating 
vascular endothelial growth factor (VEGF), received accelerated approval by the United States 
Food and Drug Administration (FDA) for the treatment of recurrent GBM in May 2009 based on 
results from two phase II trials (11, 12). However, administration of BEV along with TMZ as an 
adjuvant treatment for newly diagnosed GBM did not improve median overall survival when 
compared to patients that received TMZ monotherapy (13, 14). Nevertheless, BEV remains as 
an anti-angiogenesis therapy for recurrent GBM in United States, and it is administered 
biweekly with or without irinotecan (IRI) (approved for colon or rectal cancer). 
Local therapy: Gliadel® wafer 
Another common type of therapy for GBM is the use of drug-loaded polymer wafer, 
Gliadel®, made of biodegradable polymer poly [bis(p-carboxyphenoxy propane) sebacic acid] 
loaded with the anti-cancer drug carmustine (BCNU) (15, 16). Gliadel® had been shown to 
increase overall survival in patients with recurrent GBM as well as in patients with newly 
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diagnosed GBM (16, 17). However, studies have shown that Gliadel® wafers, along with other 
locally delivered therapeutics, suffer from the “sink effect” in which the drug is washed away in 
systemic circulation due to excessive diffusion of the drug, i.e., the concentration of the drug 
rapidly declines once it has been released from the wafer (18). New efforts are being done to 
extend the survival benefit of wafers by combining BCNU-TMZ using a novel polymeric 
formulation. Tyler B. and coworkers demonstrated that this new wafer combination results in 
higher local drug concentrations achieved and maintained by its ability to create a stable and 
hydrophobic microenvironment for both BCNU and TMZ (19). This study is also unique in that 
the two chemotherapeutic agents are delivered from one wafer with uniform release of the 
compounds into the brain parenchyma. 
Tumor treating fields: Optune™ 
Optune, a tumor treating fields (TTFields) medical device, is a novel therapeutic modality 
that was approved by the FDA for both recurrent and newly diagnosed GBM in April 2011 and 
October 2015, respectively (20). When Optune is turned on, it creates low-intensity, wave-like 
electric fields called TTFields. These TTFields are delivered by 4 adhesive patches, called 
transducer arrays, to the location of the tumor, slowly interfering with cell division (Figure 3). 
These transducer arrays are applied to the scalp and are connected to the device and battery. 
EF-14 phase III clinical trial using TTFields along with maintenance TMZ prolonged median 
overall survival to 20.9 months, which was superior to a median overall survival of 16 months in 
the control group treated with TMZ monotherapy for newly diagnosed GBM (21).  
Others 
Other therapies have been applied to recurrent GBM, including second craniotomy with or 
without Gliadel® wafers, salvage radiation, dose-dense TMZ, nitrosoureas, carboplatin, PCV 
[procarbazine, lomustine (CCNU) and vincristine], etoposide or IRI (10). However, none of them 
have shown significant improvement in the overall survival compared to the standard of care.  
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3. Clinical trials for recurrent glioblastomas and other types of brain tumors 
Adjunct therapies 
Combination chemotherapy is the strategy of using chemotherapy drugs concurrently to 
yield additive or synergistic inhibitory effects to glioma cell growth and make it difficult for cancer 
cells to develop drug resistance (22). However, no chemotherapy combination has yet been 
shown to extend survival time than current standard of care treatment for recurrent GBM 
patients through phase III studies. Current chemotherapy combinations that have been 
evaluated in clinical trials are: BEV+IRI, BEV+CCNU, BEV+TTFields, and BEV+TMZ (23-25).  
The triple-drug combination of TMZ, BEV, and IRI, named TBI, has been studied in 3 
different clinical trials treating GBM: a phase I study of 41 unresectable GBM patients 
(NCT00979017) (26), a phase II study of 75 newly diagnosed GBM subjects (NCT00597402) 
(27), and a phase I pilot study including 12 high-grade glioma (HGG) subjects (NCT00890786) 
(28). These studies demonstrated that the TBI regimen was reasonably tolerated among GBM 
and high-grade glioma patients. However, the TBI regimen has not yet been studied in recurrent 
GBM. Albeit, the FDA does not restrict physicians' practice for “off-label” use of approved 
medications or their combinations (29).  
Immunotherapy 
The recent success of cancer immunotherapy using immune checkpoint inhibitors (CPIs) 
against many otherwise untreatable cancers has raised expectations that such approaches 
could also be successfully used against GBM. For example, combination of anti-programmed 
cell death protein-1 (PD-1), anti-TIM-3, and targeted radiation showed impressive results in the 
preclinical mouse GL261 glioma model (30). There are currently several ongoing clinical trials of 
CPIs in GBM including phase III trials with Ipilimumab (blocking CTLA-4) and Nivolumab 
(blocking PD-1) (NCT02017717, NCT02617589) (31). 
Adoptive cell transfer therapies for GBM have evolved considerably over time as earlier 
work focused on less specific approaches utilizing natural killer or lymphokine-activated killer 
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cells (32). Clinical trials for these platforms have become less favored over the past decades, in 
part due to phase III evidence from solid tumor settings where infusion of cells with interleukin-2 
was not found to be superior to interleukin-2 alone (33). Of all adoptive cell transfer-based 
immunotherapies currently in development for GBM, gene-engineered CAR T cells are at the 
forefront, with encouraging results reported from several recent clinical trials (34). Structurally, 
CAR molecules consist of an extracellular, antigen-binding domain translated in tandem with 
assorted intracellular signaling regions that have differential effects on T-cell proliferation, 
effector function, and survival. To date, 4 antigens have been pursued in CAR clinical trials for 
GBM. These include EGFR variant III (35), HER2 (36), and IL13Ra2 (37). There is also interest 
in erythropoietin-producing hepatocellular carcinoma A2, although results from clinical trials 
investigating this target have not yet been released (NCT02575261).  
Experiences in the clinics show that GBM presents a particularly difficult target for 
immunotherapy, and the currently ongoing clinical trials utilizing CPIs, chimeric antigen receptor 
(CAR) T cells, or different vaccination strategies have resulted in mostly disappointing results 
(31). 
Virus-based immunotherapy 
It is worth noting that PD-1 blockade has shown impressive results against hypermutated 
GBM (38, 39), indicating that CPIs can be effective in a certain subset of patients. However, 
CPIs work by blocking the negative regulators of T cell function, thereby sustaining T cell 
activity. Consequently, tumors with low T cell infiltration (such as GBM) are unlikely to get 
significant benefit from CPI therapy. In these cases, it would be important to induce T cell 
infiltration into the tumor prior to CPI therapy. As oncolytic viruses have a potent ability to induce 
CD8+ T cell responses against tumor cells, it can be expected that precursory oncolytic 
virotherapy would enhance the effectiveness of CPIs. Therefore, combination of checkpoint 
blockade with oncolytic virotherapy (selectively kill infected cancer cells) is an attractive option 
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due to virus-induced inflammatory response in the tumor can lead to upregulation of PD-1 on T 
cells and PD-L1 on tumor cells (40). 
There are 19 current trials using oncolytic viruses against GBM (31). Of these, perhaps the 
most promising viruses are DNX-2401, PVS-RIPO, and Toca 511, all of which have shown 
complete durable responses in approximately 20% of GBM patients who received virus 
intratumorally (41-43). In Toca 511 and DNX-2401 trials, no dose-limiting toxicities were 
observed (42, 43). In the PVSRIPO trial, one death and one dose-limiting toxic effect were 
reported (41). The encouraging results obtained with PVS-RIPO, Toca511, and DNX-2401 have 
granted them a fast track designation by the FDA for expedited drug review process. 
Robust replication-induced cell death can, however, lower the amount of transgene 
produced by the infected cell. Therefore, any oncolytic virus construct that depends on delivery 
and expression of therapeutic genes must be carefully optimized. It must also be considered 
that excessive expression of immunoregulatory transgenes might have unwanted toxic side-
effects (44). Furthermore, it should not be underestimated that the GBM microenvironment 
presents a challenge for oncolytic virus delivery into the tumor, as well as effective viral 
replication and spread within the tumor. In addition, the heavy infiltration of innate immune cells 
(in both human and mouse models) and the presence glioma stem cells can render the GBM 
tissue resistant to effective viral spread, pointing out the need for robustly replicating viruses in 
order to disrupt the suppressive GBM microenvironment (31).  
4. Moving forward using localized nanomedicine 
The history of therapeutic studies for malignant gliomas is filled with attempts to deliver 
drugs or genes into the tumor cells in a cancer-selective manner, sparing surrounding healthy 
brain tissue components.  Therapeutic delivery to the brain is challenging because of two critical 
barriers: 1) the blood brain barrier (BBB), which regulates the traffic of substances between the 
blood stream and the brain, and 2) the tissue interstitial barrier, which compromises 15-20% of 
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the total brain volume, affecting the flow and intake of nutrients, metabolites, cytokines, 
neurotransmitters, and numerous molecules present in the tumor and the brain parenchyma. 
Independent of local or systemic delivery, effective penetration of therapeutic agents to diffuse 
into the highly infiltrative and not surgically accessible tumor cells is crucial to achieve maximum 
anti-tumor efficacy.  
 Nanomedicine represents a promising and versatile platform for the delivery of therapeutics 
to the brain. The current standard of care, as discussed earlier, yields only a modest therapeutic 
benefit for patients with malignant gliomas. Recent advances in local drug delivery techniques, 
along with the development of highly effective brain-penetrating nanoparticles, have significantly 
improved treatment and imaging of brain tumors in preclinical studies (45). The major 
advantage of this combined strategy is the ability to optimize local therapy, by maintaining an 
effective and sustained concentration of therapeutics in the brain with minimal systemic toxicity. 
In this thesis, we investigate the development and application of brain penetrating nanoparticles 
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Enhancing therapeutic delivery to the brain via convection enhanced delivery 
Abstract 
Convection enhanced delivery (CED) is an attractive method to bypass the blood-brain barrier 
for therapeutic delivery to the brain as well as to facilitate widespread therapeutic distribution 
within brain parenchyma by creating a continuous pressure-driven bulk flow. However, rapid 
removal of therapeutics from the brain by the physiological clearance mechanism remains a 
critical challenge to achieving widespread therapeutic delivery by CED. Nanoparticle (NP)-
based delivery systems that stay longer in the brain while convoying a high concentration of 
payloads can potentially provide widespread and efficient therapeutic delivery to the highly 
disseminated disease areas within the brain. We have recently demonstrated that CED of NPs 
designed to efficiently penetrate the highly adhesive and nanoporous brain extracellular matrix 
synergistically enhances the payload distribution within healthy and tumor-bearing brains. In this 
chapter, we overview the mechanism and current limitations of CED, as well as strategies to 
maximize the CED-mediated therapeutic and/or NP delivery to the brain. We then describe a 
detailed methodology for preclinical CED experiments, including device/animal set-up, NP 
preparation, tissue processing and image/data analysis. Finally, we conclude the chapter with a 









1.1  Key challenge to therapeutic delivery to the brain - limited therapeutic distribution 
The blood-brain barrier (BBB) is a primary impediment to the delivery of systemically 
administered therapeutic agents to the brain (1). Strategies to overcome the BBB have been 
widely explored and pre-clinically validated, including transient BBB opening via chemical (2) or 
physical (3-5) methods and circumvention of the barrier by local infusion (6, 7). The 
conventional strategy to bypass the BBB involves direct intracerebroventricular or intrathecal 
injection of therapeutics into lateral ventricles of the brain or into the lumbar spine where the 
cerebrospinal fluid (CSF) circulates, respectively (8). However, an additional challenge, 
regardless of the route of administration, is to achieve widespread therapeutic distribution in the 
brain (9). It is now well established that simple diffusion-mediated dispersion of conventional 
therapeutics, including small molecule-, and protein-based drugs, do not provide widespread 
coverage throughout highly disseminated disease areas within the brain parenchyma (10, 11). 
In addition to the slow diffusion rates, the rapid drug clearance by convective flow of the CSF, 
from brain tissue to bloodstream, remains a contributor to the suboptimal drug distribution and 
their local retention (12). The human CSF is produced at a rate of 550 mL/day, with ~100-140 
mL of CSF turning over every 4 - 5 hours (13). Thus, injected drugs carried by the interstitial 
fluid bulk flow are continuously destine to the CSF and subsequently eliminated from the brain 
parenchyma by the physiological CSF turnover (9). 
Due to the combined effect of slow diffusion and rapid clearance, the concentrations of 
locally injected drugs have been estimated to decrease by ~10-folds for every millimeter of the 
traveled distance from the site of administration (10, 14, 15). This decrease in drug 
concentrations augments with the increase in the molecular weight or size of the molecule (16), 
which is primarily attributed to the reduction in the diffusion rates, as expected from the Stokes-
Einstein diffusion equation. The bis-chloroethylnitrosourea (BCNU) wafer, Gliadel®, developed 
and clinically used to provide sustained drug concentrations within the brain also suffers from a 
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similar reality; it has been reported that the BCNU concentration reduces by ~10-folds every 
500 μm of distance away from the wafer (17). Thus, the amount of drug necessary to achieve 
therapeutic concentration only a few millimeters away from the site of administration would be 
several orders of magnitude greater than its effective therapeutic dose. The required drug dose 
can be even greater, noting that the overall distance that needs to be traveled by injected drugs 
can be as far as ~50 mm or more depending on the administration site (10). Such drug doses 
will most likely lead to significant toxicity, thereby demanding a safer method to achieve 
therapeutic concentrations throughout the target diseased areas within the brain.  
1.2 Convection enhanced delivery as a strategy to enhance distribution in the brain  
Convection enhanced delivery (CED) was initially introduced and implemented as a mean 
to bypass the BBB in early 1990s (18), but has later become appreciated as a strategy to 
facilitate widespread distribution of locally infused therapeutics (19-22). The CED involves 
continuous infusion of a solution into the brain at a predetermined rate (23). The procedure 
creates a pressure-driven bulk flow that pushes the infusate away from the administration site 
into the extracellular space of the brain parenchyma (23, 24). Thus, CED provides a markedly 
enhanced volumetric drug distribution within the brain as it is primarily mediated by convection, 
unlike the bolus injection that entirely counts on non-directional random diffusion (Figure 1.1) 
(25, 26).  
In addition, instantaneous pressure build-up is avoided by the CED due to the slow infusion, 
which reduces reflux that inevitably occurs during bolus injection (23). Further, the gradual 
infusion of CED can potentially mitigate systemic toxicity of therapeutic agents by reducing the 
amount of drugs exposed to the systemic circulation at a given time (21, 27). These unique 
advantages offered by CED have prompted the use of the technique for localized 
chemotherapeutic delivery to treat malignant gliomas, primarily glioblastoma multiforme (28, 29) 
and diffuse intrinsic pontine glioma (24, 30), of which recurrence generally occurs as far as 
centimeters away from the primary tumor site (31).    
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The CED has been also explored in various preclinical and/or clinical settings for treatment 
or diagnosis of other brain diseases beyond tumors, including neurodegenerative diseases, 
epilepsy, stroke, traumatic injuries and brainstem lesions (32-37). Specifically, the utility of CED 
has been expanded to achieve widespread delivery of a wide array of therapeutic or diagnostic 
agents, including monoclonal antibodies, therapeutic toxins, proteins, imaging tracers as well as 
drug and gene delivery systems (7, 18, 21, 38-40). Table 1.1 lists general advantages and 
disadvantages around the use of CED in comparison to other local or systemic administration 
modalities commonly applied to brain delivery.   
Table 1.1: Advantages and disadvantages of CED. 
Advantages Disadvantages 
• Bypasses BBB 
• Reduces risk of local and systemic 
toxicity 
• Widespread and uniform delivery of 
agents by pressure-driven continuous 
bulk flow 
• Distribution minimally affected by 
molecular weights of agents 
• Relatively invasive procedure 
• Prolonged infusion times 
• Potential build-up of intracranial 
pressure 
• Requires refilling for a long-term 
infusion 
 
Figure 1.1: Volume of distribution achieved by bolus injection versus CED. (A) A 
catheter is inserted into the brain tumor (red) or a cavity created after tumor resection, and 
therapeutic agents (blue) are continuously infused. Schematics (upper panel) and diffusion 
profiles (i.e. concentration gradients away from the administration site; lower panel) of 
therapeutic agents (blue) administered by (B) bolus injection and (C) CED. The CED provides 
a marked greater therapeutic distribution compared to bolus injection that counts solely on 
simple diffusion. CED Reproduced from Seo, Y.E. et al. 2017 with permission from Elsevier.    
 A                          B    Bolus      C       CED                                              
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• Less prone to human errors 
• Reduces backflow 
 
1.3 Challenges for therapeutic distribution in the brain by CED  
While the CED provides a method to enhance drug distribution within the brain, multiple 
studies have revealed that the benefit is rapidly lost due to the physiological fluid clearance 
mechanism described above (23, 25, 41). It has been reported that the peak volume of drug 
distribution precipitously reduces as early as 30 minutes after CED  and drugs are often found 
completely removed from the brain within a few hours (42). Of note, the clearance is even 
greater in the brains of patients with diseases characterized by increased vascular permeability 
and interstitial pressure, such as tumors (43-45).  
One of the methods to circumvent the clearance problem involves prolonging the infusion of 
therapeutic agents over days using an implantable catheter, which has shown proof-of-principle 
benefits in treating brain tumors (46-51). However, widespread clinical use of this long-term 
infusion modality is limited by potential risk of infection and mechanical injury, need for constant 
monitoring of drug toxicity and complex and high-cost catheter design.  As an alternative 
approach, nanoparticle (NP)-based delivery systems have been widely explored in preclinical 
settings to provide sustained therapeutic concentrations in the brain. Due to their larger sizes, 
therapeutic NPs carrying a high concentration of payloads delivered into the brain parenchyma 
stay longer without being rapidly cleared unlike drugs administered “naked” (52, 53). NPs can 
carry and deliver controlled release of various types of payloads, ranging from small molecule 
drugs to biological macromolecules (39, 53, 54). Further, NPs can be designed to facilitate 
specific cell targeting and subsequent uptake (54, 55), providing another mechanism by which 
rapid drug clearance from the brain is avoided.  
While NPs can potentially delay the drug clearance, released payloads spread in the brain 
via slow diffusion remains identical to directly injected naked drugs. Thus, NPs must broadly 
disperse throughout the brain parenchyma via CED, followed by timely release of payloads, to 
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provide widespread therapeutic coverage within the brain. However, widespread NP distribution 
is not readily achieved due to the presence of highly adhesive and nanoporous brain 
extracellular matrix (ECM) that fills the brain extracellular space through which NPs spread in 
the brain (56, 57). The brain ECM is composed of negatively charged or hydrophobic 
macromolecules, including hyaluronic acids, proteoglycans, glycosaminoglycans and fibrous 
proteins (58-60), which hampers NP transport in the brain via multivalent adhesive interactions 
such as electrostatic and hydrophobic interactions (56, 61). In addition, these macromolecules 
form a dense meshwork, rendering the ECM a steric barrier to NP diffusion within the brain (39, 
54, 56). The pore sizes of the brain ECM has been previously estimated to be 38 - 64 nm (62), 
but we have recently re-evaluated them using non-adhesive probes to be as large as or 
potentially greater than 110 nm (56). Physicochemical barrier properties of the ECM within 
tumor tissues are most likely distinct from those of normal ECM due to significant changes in 
cellularity and macromolecular compositions that are highly varied depending on the type of 
tumor (63-65). There have been several reports suggesting that the pore sizes of tumor ECM 
may be smaller than 100 nm (62, 66). Of note, interstitial pressure build-up in tumor tissues (44, 
67) often promotes outward brain tumor cell migration and consequently, greater volume of 
therapeutic distribution is likely needed (39, 67-69).   
1.4 Strategies to enhance NP distribution in the brain following CED  
As described above, brain ECM is an adhesive and steric barrier to NP diffusion. Thus, 
NPs possessing small particle diameters to fit through the ECM pores as well as non-adhesive 
surface coatings that resist adhesive interactions with ECM components would be able to 
penetrate the brain tissue. Indeed, we have previously demonstrated that NPs as large as ~110 
nm efficiently penetrate rodent and human brain parenchyma ex vivo and in vivo, but only if the 
particle surfaces are densely passivated with hydrophilic and neutrally charged polyethylene 
glycol (PEG) (Figure 1.2) (56).  Specifically, NPs possessing diameters of ~100 nm were shown 
to efficiently diffuse through normal brain ECM when their surfaces were coated with PEG at the 
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surface densities of ≥ 8 PEG molecules per 100 nm2 particle surface area (56). However, 
minimal surface PEG density cut-off may vary depending on particle size due to the difference 
in surface curvature. We also note that smaller particle diameters may be needed for efficient 
NP penetration through tumor ECM meshes. More recently, we found that CED of this “brain-
penetrating” NP (BPN) resulted in widespread distribution in healthy or tumor-bearing brain 
striatum; in contrast, the distribution of similarly sized uncoated or conventionally PEGylated 
NPs was confined to the site of administration despite the pressure-driven convective flow 
provided by the CED (38, 65, 70-74). Importantly, NPs must retain the physicochemical 
properties required for efficient brain penetration in the physiological brain environment (i.e. 
brain interstitial fluid or CSF). 
The physicochemical properties and stability that allow efficient brain penetration are 
likely applicable commonly to nano-scale particulate matters regardless of type of core 
materials, including polymers, lipids and inorganic compounds. We have previously 
demonstrated that BPNs formulated with chemically distinct core polymers equally provide 
widespread distribution in rodent brain tissue in vivo following CED (38, 65, 70-72, 74). Other 
than PEG, various coating materials have been used to endow NP-based delivery systems with 
colloidal stability; those include but are not limited to sugars, pluronics, polyglycerols, polyacrylic 
and polyvinyl polymers (75, 76). However, these materials, often possessing chemical 
properties similar to PEG (i.e. hydrophilic and neutrally charged), can potentially be utilized to 
engineer BPNs although it is yet to be experimentally determined. We note that while not 
necessarily geared specifically towards creating NPs capable of penetrating brain ECM, a 
variety of NPs have been preclinically investigated in conjunction with CED. Interested readers 
are referred to a recent review article (54).  
Adhesive NPs small enough to avoid steric obstruction imposed by the brain ECM can 
widely spread throughout the brain parenchyma following CED if NPs are administered at a very 
high concentration (38). Specifically, CED of uncoated NPs administered at 25 mg/ml exhibited 
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the volumetric distribution approaching that achieved by identically administered BPN at 0.1 
mg/ml (38). This phenomenon is likely due to potential masking of the adhesive moieties of 
ECM by an excess of adhesive NPs, thereby enabling the residual NPs to pass through the 
ECM pores without being associated with ECM meshes. However, it should be noted that this 
approach is likely prone to dose-limiting toxicity, particularly when payloads possess intrinsic 
toxicity such as chemotherapeutic agents.  
           
 Alternatively, NP distribution in the brain following CED can be enhanced by 
manipulating the barrier properties of ECM. In particular, the pore sizes can be transiently 
modulated by chemical or physical methods. As an example, we have recently reported that 
distribution of BPNs in rodent brain following CED significantly increases when administered in 
a hyperosmotic solution (38). This is most likely attributed to the mechanism described in a prior 
Figure 1.2: Ex vivo diffusion and in vivo distribution of nanoparticles (NPs) in 
human and rodent brain tissues. (A) Representative particle trajectories for non-
PEGylated (i.e. adhesive) and PEGylated (i.e. non-adhesive) NPs of various sizes in 
brain tissues freshly harvested from humans. (B) Direct comparisons of the distribution 
of non-PEGylated (red) and PEGylated (green) NPs of various sizes following 
intracranial co-injection into mouse brains. Scale bar = 50 μm. Reproduced from 
Nance, E. et al. 2012 with permission from The American Association for the 
Advancement of Science. 
 A Non-PEGylated  PEGylated  B Non-PEGylated   PEGylated      Overlay                                              
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study that hyperosmolar saline administered in brain tissue leads to enlargement of the ECM 
mesh spacings as water is drawn out of cells into the extracellular space via an osmotic gradient 
established by the hyperosmolar saline (77, 78). Likewise, it has been recently demonstrated 
that focused ultrasound, by transiently enlarging the extracellular space, can enhance NP 
dispersion in the brain (79). 
1.5 CED in clinical trials 
Previous and ongoing clinical trials involving the implementation of CED for treating 
diseases affecting the central nervous system (CNS) are listed in Table 1.2. Presumably due to 
the somewhat invasive nature of the procedure, most (i.e. 37 out of 41) of trials were conducted 
in patients with malignant gliomas who were already receiving surgery. The rest covers 
neurodegenerative disorders, including Parkinson’s disease (NCT01621581, NCT00921128), 
aromatic L-amino acid decarboxylase (AADC) deficiency (NCT02852213) (80, 81) and Gaucher 
disease (82). A majority of trials to date involve delivery of naked therapeutic agents for cancer 
therapy (21), but the number of trials that include delivery systems is increasing, particularly 
regarding gene therapy applications. Specifically, viruses (NCT02852213, NCT01621581) and 
liposomes (83-86) have been or are currently being explored in clinical settings to achieve 
widespread therapeutic transgene expression following CED.  
Table 1.2: Clinical trials conducted to evaluate CED for treating CNS diseases as of late 2018. 
Target 
Disease 
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2. Materials and Methods 
2.1  CED Apparatus 
The CED apparatus is composed of two main components, including the ultra-precise 
rodent “U”-stereotaxic frame (Stoelting, Wood Dale, IL) and the Chemyx Nanojet injector 
module (Chemyx, Stafford, TX) (Figure 1.3). The primary components of the stereotaxic frame 
are (a) non-rupture ear bars, which help place rodent head flat and parallel to the table of 
operation, (b) 100 micron 3-axes manipulator arm, which allows movement of a probe holder in 
x-, y- and z-axis directions (measured in mm), (c) a corner clamp probe holder that grips the 
syringe header and (d) an adaptor where the rodent head is placed. The second component of 
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the CED apparatus, injection module, consists of (e) Nanojet control box where infusion 
parameters, including infusion rate, volume and type of syringe, are selected and (f) Nanojet 
syringe header, which is connected to the control box and holds the syringe in place. We also 
refer this part to “injector”, as it controls the infusion rates as programmed by the control box.     
            
2.2 Syringe and cleaning solutions  
The infusate solution carrying therapeutics or NPs is loaded into a 5 or 50 µL Hamilton 
Neuros syringe (Hamilton, Reno, NV) connected to a 33-gauge needle for treating mice or rats, 
respectively. This syringe is designed to endow an enhanced needle rigidity specifically for 
applications to brains, which allows infusion of a micro-volume of fluid precisely into a desired 
location within the brain while minimizing the risk of injection site damage (110). There are five 
different types of needle catheters used in CED, including end-port catheter, multi-port catheter, 
porous-tipped catheter, balloon-tip catheter and stepped-down catheter (111) (see (21) for 
details). We routinely use the stepped-down catheter designed to allow feasible adjustment of a 
Hamilton Neuros syringe. This catheter is composed of a needle sleeve with or without a blind 
stop and a needle that passes through the sleeve hollow. The distance between the sleeve end 
and needle tip or the length of the needle exposed from the sleeve end is defined as the step 
distance, which can be manually adjusted to range 1 to 20 mm (112). For the former set-up 
Figure 1.3: CED apparatus. The 
CED device is composed of two 
distinct functional compartments, 
including structural (i.e. stereotaxic 
frame) and injection (injection 
module) elements. The primary 
components of the former include 
(a) non-rupture ear bars, (b) 100 
micron 3-axes manipulator arm, 
(c) a corner clamp probe holder 
and (d) an adaptor. The latter is 
composed of (e) Nanojet control 
box and (f) Nanojet syringe 
header or injector.  
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(with a blind stop), the step distance is pre-determined and maintained by the sleeve-end blind 
stop placed on top of the skull during the administration. In contrast, needle sleeve of the latter 
passes through the burr hole and the step distance can be subsequently adjusted for desired 
stereotaxic applications. The term “stepped” originated from a sharp dimensional transition from 
the wider needle sleeve to a narrower needle (112). Of note, a 1-mm step distance has been 
previously optimized to minimize the possibility of reflux and leakage in rodent brain (Figure 1.4) 
(112), and thus most widely employed for CED application.    
 
A fresh solvent used to carry and administer therapeutics and/or NPs (e.g. ultrapure 
water, medical-grade saline, etc.) is utilized to rinse the syringe between sequential infusions 
when multiple CED experiments are involved. A biodegradable and non-detergent-based 
cleaning agent such as the Cleaning Solution Concentrate (Hamilton, Reno, NV) is used to 
rigorously wash the syringe and needle upon the completion of CED experiments in order to 
avoid potential clogging and/or contamination. Ultrapure water in conjunction with ethanol or 
acetone are used for final wash. 
2.3 Preparation of NPs and infusate solutions  
Based on aforementioned physicochemical design criteria required for efficient brain tissue 
penetration (see section 1.4; (54, 56)), we have engineered numerous BPN formulations for 
delivery of a wide array of payloads, ranging from small molecule chemotherapeutics (63, 74) to 
Figure 1.4: Adjustment of stepped-down catheter for optimal infusion into the striatum. (A) Either a 
long (i.e. 2 mm) step distance or (B) an optimal 1-mm step distance with a short cortical distance (i.e. 
distance between cerebral cortex and catheter step or the end of needle sleeve) increases the probability 
of reflux and/or leak, leading to a suboptimal infusate distribution (gray shade). (C) A 1-mm step distance 
with a longer cortical distance minimizes the probability of reflux and/or leakage, thereby leading to a 
greater infusate distribution. Reproduced from Yin, D. et al. 2010 with permission from Elsevier. 
 A   B   C  
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reporter or therapeutic nucleic acids (65, 71, 72). For the purpose of this chapter, however, we 
use commercially available latex beads possessing highly controlled particle diameters and 
defined surface chemistries as a model therapeutic delivery NP. In particularly, we utilize 
fluorescently labeled carboxylated polystyrene beads (PS-COOH) (Life Technologies, Grand 
Island, NY) to engineer model BPNs (i.e. PS-PEG) (56), while the unmodified PS-COOH NPs 
serve as a conventional control that readily interacts with brain ECM components and thus 
cannot efficiently penetrate the brain parenchyma (56). Methoxy-PEG-NH2 (5 kDa; Creative 
PEGWorks, Durham, NC), N-hydroxysulfosuccinimide (NHS; Sigma, St. Louis, MO), 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC; Invitrogen, Carlsbad, CA) and 200 mM sterile 
sodium borate buffer pH 8.2 (Growcells, Irvine, CA) are used to synthesize model BPNs 
possessing dense surface PEG coatings. All NPs are washed in Amicon Ultra-0.5 mL 100 K 
MW filters (Millipore Sigma, Burlington, MA), and characterized with a Zetasizer NanoZS 
(Malvern Instruments, Columbia, MD) and 1H NMR (400 MHz; REM400; Bruker, Billerica, MA).  
Saline-based infusate solutions possessing different osmolality are prepared in ultrapure 
DNase/RNase-free water (ThermoFischer Scientific, Waltham, MA) and filtered through a 0.20 
µm sterile syringe filter (Corning Incorporated, Corning, NY). Specifically, we use 0.9% (~300 
mOsm/kg) or 3% (~1000 mOsm/kg) NaCl solution as an isotonic or hypertonic infusate solution, 
respectively. Osmolality is measured using the Vapro® Vapor Pressure Osmometer (EliTech 
Wescor, Logan, UT).   
2.4  Animal Set-up 
While technically any type of rodents can be used, we routinely conduct CED experiments 
with two different strains each for mice (20 – 30 g), including CF-1 (Jackson Laboratory, Bar 
Harbor, ME) and C57BL/6J mice (Charles River, Wilmington, MA), and rats (120 – 
200 g), including Fischer 344 and Sprague Dawley rats (Harlan Laboratories, Frederick, MD). 
Of note, inbred rodents are often preferred when an identical genetic background is desired, 
such as in case of gene therapy applications (113). Animals are housed in a standard animal 
30 
 
husbandry facility and are given a free access to food and water. All animals are treated in 
accordance with the policies and guidelines of the Johns Hopkins University Animal Care and 
Use Committee.  
A mixture of ketamine and xylazine is used to anesthetize rodents as routinely conducted 
(114). Optixcare eye lubricant (CLC Medica, Ontario, Canada) and Betadine® antiseptic 
solution (Purdue Pharma L.P., Stamford, CT) are used for lubricating eyes and sterilizing skin, 
respectively, prior to surgery. A scalpel (Aspen Surgical, Caledonia, MI) equipped with a sterile 
surgical blade (Cincinnati Surgical, Cincinnati, OH) is used to create a midline scalp incision, 
and a micro-drill (Harvard Apparatus, Holliston, MA) is utilized to make a small 1.0-mm burr hole 
through the rodent skull. We use biodegradable sutures (Polysorb Braided Absorbable Sutures 
5-0; Medtronic, Minneapolis, MN) to seal the incision and bacitracin as a topical antibiotic, 
following CED experiments.  
2.5 Tissue processing and confocal microscopy  
For brain tissue fixation and cryoprotection, we use a ready-to-use working solution 
composed of 4 % formaldehyde (i.e. equivalent to 10% formalin) dissolved in a phosphate buffer 
(Sigma-Aldrich, St. Luis, MO) and gradient sucrose (Sigma-Aldrich, St. Luis, MO) solutions 
prepared by dissolving sucrose in Dulbecco’s phosphate-buffered saline (DPBS, 1X) 
(Corning™, Manassas, VA) at 10%, 20%, and 30% w/v, respectively. Tissue-Tek optimal cutting 
temperature (OCT) compound (Sakura Finetek, Torrance, CA) is used to prepare frozen tissue 
samples for subsequent cryosection with a research cryostat (model CM3050 S, Leica 
Biosystems, Buffalo Grove, IL). Dako fluorescence mounting medium (Dako, Carpinteria, CA) is 
utilized to mount cryosectioned brain tissue slices. Confocal microscopy of the tissue slices is 
conducted by using a Zeiss LSM 710 confocal laser scanning microscope (Carl Zeiss 
Microscopy, Jena, Germany) equipped with a 5x/0.25 M27 air objective (Carl Zeiss Microscopy, 
Jena, Germany). We use Metamorph® image analysis software (Metamorph, Sunnyvale, CA), 
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ImageJ (NIH, Bethesda, MD) and Imaris (Bitplane, South Windsor, CT) for image analysis 
and/or reconstruction. 
The outcomes of CED applications are contingent to the selection of different variables, 
including device arrangement, infusion parameters, brain coordinates and NP design. We here 
describe how we adjust these variables to achieve widespread distribution of model NPs 
following CED in rodent brains.  
2.6 CED device arrangement 
To ensure consistent and stable infusions, each component of the CED apparatus must 
be assembled and adjusted properly following the manufacturer’s manual. While the syringe 
header (i.e. injector) presses the syringe plunger for infusion as programmed by the control box, 
all other components should be fully stabilized. Specifically, it is critical to securely fasten the 
base of the 3-axes manipulator arm to avoid its rotation and the corner clamp probe holder to 
firmly hold the syringe header during the procedure (Figure 1.5). In addition, the screw on the 
syringe header must be fastened to ensure that a syringe is tightly associated with the header 
during the infusion. The stereotaxic frame must be placed on a flat surface on which a rodent is 
laid face-down for a subsequent CED experiment.   
    
Figure 1.5: CED device 
arrangement. All 
components should be fully 
stabilized prior to CED 
experiments. Specifically, it is 
critical to securely fasten (a) 
the corner clamp probe 
holder to firmly hold the 
syringe header during the 
procedure, (b) the base of 3-
axes manipulator arm to 
avoid its rotation and (c) the 
screw on the syringe header 
must be fastened to ensure 
that a syringe is tightly 
associated with the header 





2.7 Determination of infusion parameters 
Infusion parameters are generally perceived as important factors that dictate the final 
outcomes of CED. However, reports that have systemically evaluated the impacts of infusion 
parameters are rare. It is conceivable that increase in the infusion rate, by potentially increasing 
the pressure gradient, may improve the distribution of therapeutics or NPs within the brain 
tissue following CED. However, greater infusion rates have been shown to enhance reflux, 
thereby offsetting their otherwise positive impacts on the distribution (115). For example, it has 
been demonstrated that the difference in distribution of soluble proteins (i.e. bovine serum 
albumin; 69 kDa) in rat brains was negligible regardless of infusion rates ranging from 0.1 to 5.0 
µL/min due to the greater refluxes at higher rates (25). However, it has been also shown that the 
reflux can be minimized by a careful optimization of the step distance where no significant reflux 
was observed up to the infusion rate of 10 µL/min when 1-mm step distance was employed 
(116). We note that infusion rates of 0.1 to 1 µL/min and 0.33 to 5 µL/min are commonly used 
for mice (85, 117-119) and rats (38, 116, 120-122), respectively. Based on these previously 
reported ranges and our in-house optimization, we infuse overall volumes of 2 and 20 μL at 
rates of 0.2 and 0.33 μL/min for mice and rats, respectively (38, 72, 73).  
As described above, hypertonic infusate solution can enhance volume of NP distribution by 
osmotically increasing the brain ECM pore sizes (77, 78) when NP diffusion in the brain tissue is 
primarily hindered by steric hindrance imposed by the ECM mesh (e.g. BPN or PS-PEG NP) 
(Figure 1.6) (38).  However, conventional NPs (e.g. PS-COOH NP) that readily interact with 
ECM components are unable to fully exploit this mechanism due to the contribution of adhesion 
on their diffusion in brain tissue (38). It should be also noted that the colloidal stability of NPs 
must be retained in a hypertonic infusate solution as the increase in NP sizes in an infusate 
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solution can offset the effect of infusate-mediated enlargement of the ECM pores on steric 
hindrance to NP diffusion (38).     
                                 
2.8 NP formulation and characterization   
Model BPNs are engineered by amidation reaction between carboxyl groups on the surface 
of fluorescently labeled PS-COOH NPs and methoxy-PEG-NH2, following a previously reported 
protocol (123, 124) with some modification. Briefly, PS-COOH NPs are diluted in ultrapure water 
to the NP concentration of 1.25% w/v (i.e. 4-fold dilution from the stock concentration), followed 
by an addition of methoxy-PEG-NH2 at two-molar equivalents of the surface carboxyl groups. 
Subsequently, 10-molar equivalents (to methoxy-PEG-NH2) of NHS is added to the mixture and 
diluted with a 200 mM borate buffer to the final NP concentration of 0.375% w/v. Finally, 1-molar 
equivalent (to methoxy-PEG-NH2) of EDC is added and mixed until all reagents are fully 



















































 A  
 B  
Figure 1.6: Effect of infusate osmolality on the volume of distribution of NPs in 
mouse brains following CED. (A) Representative tissue sections depicting the 
coronal plane within the mouse striatum where PS-PEG (red) and PS-COOH (green) 
NPs were infused via CED. Yellow fluorescence represents overlay of two different 
types of NPs. Scale bar = 1 mm. (B) Volumetric distribution of PS-PEG and PS-COOH 
NPs quantified by an image-based MATLAB analysis described in section 3.5. *p < 
0.05 denotes a statistically significant difference. Reproduced from Zhang, C. et al. 
2017 with permission from Elsevier. 
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in Amicon Ultra-0.5 mL 100 K MW filters by extensive centrifugation to remove unreacted 
species as well as to recover the starting NPs concentration (i.e. 5% w/v) and then stored at 4 
°C until use.  
NPs are suspended in 10 mM NaCl for fundamental physicochemical characterization via a 
Zetasizer NanoZS. Specifically, hydrodynamic diameter and polydispersity index are measured 
by dynamic light scattering (DLS) with 90° scattering optics. The ζ-potential, an indicative of NP 
surface charge, is determined by laser Doppler anemometry, also known as laser Doppler 
velocimetry. Table 1.3 demonstrates physicochemical properties of PS-COOH and PS-PEG (i.e. 
BPN) NPs described above. The surface PEG density is quantified by 1H NMR as previously 
reported (56). Briefly, PS-PEG NPs are fully dissolved in a mixture of deuterated chloroform and 
trifluoroacetic acid containing 0.5% w/v BTSB and subjected to 1H NMR measurement. Total 
amount of PEG molecules on NP surfaces are then determined using a standard curve 
established with 1H NMR integrals measured at various concentrations of 5 kDa methoxy-PEG-
NH2 (3.6 ppm) dissolved in the same deuterated solvent mixture. In parallel, NP surface area is 
estimated by the hydrodynamic diameter of NP measured by DLS and the density of PS 
provided by the manufacturer (i.e. 1.055 g/ml). The surface PEG density is then calculated by 
dividing the total amount of PEG molecules with NP surface area. The colloidal stability of NPs 
in a physiologically relevant brain microenvironment is assessed by incubation of NPs in 
artificial CSF at 37 °C, followed by DLS measurement at different time points post-incubation. 
Likewise, the colloidal stability of NPs in a pre-determined infusate solution over time is 
assessed by DLS. Fresh NPs are store at 4 °C and diluted to 1 mg/ml in an infusate solution 












± SEM (nm)a 
Polydispersity 
index (PDI)a 
ζ-potential ± SEM 
(mV)b 
PS-COOH 42 ± 10 0.05 -39 ± 3 
PS-PEG 69 ± 8 0.04 - 3 ± 1 
a Hydrodynamic diameter and polydispersity index (PDI) were measured by dynamic light scattering (DLS) 
in 10 mM NaCl at pH 7.0. Mean ± SEM (n ≥ 3).  
b ζ-potential was measured by laser Doppler anemometry in 10 mM NaCl at pH 7.0. Mean ± SEM (n ≥ 3).  
 
2.9 Animal preparation and CED execution 
Rodents are anesthetized by an intraperitoneal administration of ketamine and xylazine at 
75 and 7.5 mg/kg, respectively. We then lubricate eyes, shave the hair on the head and sterilize 
the skin with an antiseptic solution. Subsequently, a midline scalp incision is made to expose 
the coronal and sagittal sutures of the skull and a small 1-mm burr hole is made by carefully 
drilling through the skull. It is critical not to damage the brain tissue (e.g. hemorrhage) during 
this procedure by perforating beyond the skull.  
We sequentially wash the Hamilton Neuros syringe with ethanol or acetone and with 
ultrapure water or an infusate solution prior to the loading of the syringe with a NP-suspended 
infusate solution. The syringe filled with a NP suspension is then vertically mounted onto the 
Nanojet syringe header. Of note, the syringe is subjected to the two-step wash between 
consecutive injections to avoid potential NP contamination when multiple CED experiments with 
different NP types are involved.    
We most routinely conduct CED experiments targeting the striatum where several preclinical 
neurological disease as well as orthotopic brain tumor models are often established (125), while 
several other anatomical locations can potentially be target sites (e.g. hippocampus for 
Alzheimer’s disease). The syringe is lowered to a depth of 2.5 mm from the dura at the 
coordinate of 2 mm lateral to and 0.5 mm anterior to bregma for mice (Figure 1.7A), and to a 
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depth of 3.5 mm from the dura at the coordinate of 3 mm lateral to and 0.5 mm posterior to 
bregma for rats (Figure 1.7B) (126).     
                           
The pre-infusion sealing time of 5 - 10 minutes is applied after inserting the catheter into the 
brain in order to minimize tissue damage and to provide tissue-syringe equilibration (see Figure 
1.8 for animal set-up) (25), and then infusion is commenced as programmed by the control box. 
The syringe should be withdrawn slowly (i.e. at a rate of 1 mm/min) 5 minutes after the 
completion of a CED experiment to minimize the reflux. Subsequently, animals are placed on a 
heating pad for quick recovery while the skin opening is washed with a sterile medical-grade 
saline and sutured with biodegradable sutures, followed by topical application of an antiseptic.  
              
Figure 1.7: Coordinates to infusing therapeutics or NPs into 
rodent striatum. A stepped-down catheter with a 1-mm step distance 
points (A) a mouse coordinate of medial-lateral (ML) 2 mm, anterior-
posterior (AP) 0.5 mm and dorsal-ventral (DV) 2.5 mm, and (B) a rat 
coordinate of ML 3 mm, AP -0.5 mm and DV 3.5 mm. 
 A  
 B  
Figure 1.8: Final CED set-up with rodents 
mounted onto stereotaxic frames. Rats are 
under anesthesia and stepped-down catheters 
are inserted into rat brains targeting striatum 





2.9 Tissue processing and imaging analysis 
Using the model BPNs, we have confirmed the previous finding that the volume of NP 
distribution remains consistent from immediately up to 24 hours after the completion of CED 
(41, 122). We thus routinely harvest brain tissues immediately after the infusion and fix the 
tissue with 4% paraformaldehyde for 24 hours. Subsequently, the brain tissues are immersed in 
cryoprotective gradient sucrose solutions and then frozen at -80 °C. For the cryosection, frozen 
brain tissues are first equilibrated in a cryostat for more than 30 minutes at a chamber and an 
operating temperature of -24 and -22 °C, respectively. The brain tissues are then mounted on 
the tissue stage, firmly secured with the OCT compound and sectioned at ± 2 mm of the coronal 
infusion plate with a section thickness of 50 and 100 µm for mice and rats, respectively. Slides 
with tissues sections are subsequently fixed with the Dako fluorescence mounting medium and 
stored at 4 °C until confocal microscopy. While fixed tissue samples are generally considered 
amenable to a long-term storage at 4 °C (127, 128), it has been also reported that the 
autofluorescence often observed with fixed samples increases with the storage period (129). 
We thus conduct confocal microscopy of tissue sections no later than a few days of CED 
experiments.      
We acquire 2D images of fluorescent NP distribution within the striatal tissue sections 
captured through the 5x/0.25 M27 air objective using a Zeiss LSM 710 confocal laser scanning 
microscope. We start from the tissue section of the coronal infusion plate and take images of all 
sections exhibiting NP fluorescence beyond background. The laser power and the master gain 
are carefully adjusted using the range indicator to prevent saturation of fluorescence. Other 
software settings, including but not limited pinhole size, scan zoom and tile numbers, are also 
adjusted depending on type of fluorophore, region of interest, thickness of tissue sections, etc.    
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It is critical to properly subtract background fluorescence to accurately quantify the NP 
fluorescence signal and its coverage area.  We use a custom-made MATLAB script featuring a 
binarization algorithm named Otsu’s thresholding that distinguishes the pixels with positive (i.e. 
foreground) fluorescence signals from those with background signals (55). The code then 
quantifies background-subtracted NP-positive area in each tissue section and the volume of NP 
distribution is finally calculated by multiplying the measured areas with the thickness between 
individual sections. Images of individual sections are stacked and aligned by Metamorph® 
image analysis software and StackReg plugin functionality of ImageJ, respectively. Finally, 3D-
rendered volume of NP distribution is created by Imaris (Bitplane, South Windsor, CT) at 10% 
maximum fluorescent intensity (Figure 1.9).     
        
3. Notes for troubleshooting 
 Cleaning of needle sleeve 
Use of the stepped-down catheter without a blind stop involves insertion of the sleeve-
end into the brain tissue. During the catheter insertion and subsequent CED experiments, brain 
tissue residues and/or blood often squeeze into the sleeve hollow, which cannot be cleared by 
the standard cleaning procedure described in an earlier section. We thus recommend that the 
 A   B  
Figure 1.9: Workflow for image-based analysis of NP distribution in the brain. (A) 
Representative 2D images of consecutive rat brain tissue sections away from the coronal plane 
of infusion captured by confocal microscopy. Red fluorescence indicates model BPNs (i.e. PS-
PEG NPs) administered into the rat striatum via CED. (B) Representative 3D-rendered volumetric 
distribution of BPNs created by stacking and aligning the series of 2D images. Scale bar = 1 mm.  
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sleeve should be slid towards the syringe to expose the needle beyond the step distance and 
completely remove the remnant biological specimen by alcohol swipe. It should be noted that 
residual tissues and/or blood clots can potentially contaminate brain tissues of rodents 
undergoing future CED experiments.     
Removal of air bubbles 
The syringe plunger should be pulled up slowly to minimize the aspiration of air into the 
syringe during the sample loading. Nevertheless, we occasionally encounter air bubble 
accumulation within needle and/or syringe, which often promotes pressure spikes and reflux 
during the CED experiments, thereby leading to suboptimal distribution of therapeutics or NPs in 
the brain (7, 130). We also note that air bubbles in the infusate solution would be included in a 
preset volume of infusion and thus a fraction of sample would be left within the syringe without 
being administered (i.e. infusion of a lower dose than planned). We thus recommend that the 
syringe is loaded with an excess of sample volume and purged at a high infusion rate (i.e. no 
greater than 16.7 µL/min) for a few minutes to remove air bubbles prior to the catheter insertion 
into the rodent brain (39, 131). 
4. Conclusions 
In this chapter, we have introduced a marriage of CED and BPN as an attractive strategy to 
achieve widespread distribution of therapeutic or diagnostic payloads in the brain following local 
administration. We have walked through rationales, materials, methods and a few 
troubleshooting remarks based on our expertise and experience as well as findings from 
relevant studies reported by excellent scientists and clinicians devoted to the field. The 
consolidated efforts have led to multiple clinical trials as described earlier and the safety of CED 
procedure is now well established in humans. However, later stage trials have revealed 
technical shortcomings that need to be addressed to fulfil its therapeutic potential, which include 
design and refinement of CED compartments and parameters (21). In addition, combined 
40 
 
approach of CED and NP-based delivery systems, including BPNs, is yet at its infancy with 
most of the studies at their preclinical stages. Encouragingly, the field has recently experienced 
expansion regarding simultaneous optimization of CED procedure and NP engineering, and 
lessons learned will pave a way for its clinical development.  
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Widespread gene transfer to brain tumors via synthetic polymer-based DNA nanoparticles 
Abstract 
Gene therapy of malignant gliomas has shown a lack of clinical success to date due in part to 
inability of conventional gene vectors to achieve widespread gene transfer throughout highly 
disseminated tumor areas within the brain. Here, we demonstrate that newly engineered 
polymer-based DNA-loaded nanoparticles (DNA-NP) possessing small particle diameters (~50 
nm) and non-adhesive surface polyethylene glycol (PEG) coatings efficiently penetrate brain 
tumor tissue as well as healthy brain parenchyma. Specifically, this brain-penetrating 
nanoparticle (BPN), following intracranial administration via convection enhanced delivery 
(CED), provides widespread transgene expression in heathy rodent striatum and an aggressive 
brain tumor tissue established orthotopically in rats. The ability of BPN to efficiently traverse 
both tissues is of great importance as the highly invasive glioma cells infiltrated into normal 
brain tissue are responsible for tumor recurrence. Of note, the transgene expression within the 
orthotopic tumor tissue occurred preferentially in glioma cells over microglial cells. We also 
show that three-dimensional (3D) multicellular spheroids established with malignant glioma 
cells, unlike conventional two-dimensional (2D) cell cultures, serve as an excellent in vitro model 
reliably predicting gene vector behaviors in vivo. Briefly, DNA-NP possessing greater surface 
PEG coverage exhibited more uniform and higher-level transgene expression both in the 3D 
model and in vivo, whereas the trend was opposite in 2D culture. The finding here alerts that 
gene transfer studies based primarily on 2D cultures should be interpreted with caution and 
underscores the relevance of 3D models for screening newly engineered gene vectors prior to 






Despite the most advanced multimodal therapeutic regimen, median survival of malignant 
gliomas remains ~ 14 months (1). Gene therapy potentially provides an alternative means to 
achieve more specific and powerful as well as longer-lasting therapeutic benefits. However, its 
clinical relevance is yet to be addressed due in large part to suboptimal gene transfer efficacy. 
Given the highly aggressive, invasive and infiltrative nature of malignant gliomas, inability of 
conventional gene vectors to provide a widespread therapeutic transgene expression is an 
utmost challenge (2-4). We have previously determined the brain extracellular matrix (ECM) to 
be a critical adhesive (i.e. hydrophobic and negatively charged) and steric diffusional barrier, 
and established design criteria for engineering nanoparticle-based therapeutic delivery systems 
that can efficiently spread through the ECM (5-7). Specifically, we found that nanoparticles with 
diameters small enough (≤ ~110 nm) to fit through the ECM pores while possessing non-
adhesive dense surface polyethylene glycol (PEG) coatings rapidly penetrated rodent and 
human brain tissues (5, 8-10).     
While being well-characterized for outstanding efficacies as a polymeric gene delivery 
platform, widespread use of polyethylenimine (PEI) is largely discouraged by its safety concern 
(11, 12). However, we note that PEI toxicity is often overstated based on in vitro studies where 
conventional cytotoxicity is measured with only one or two cell types at very high doses that 
would unlikely be translatable in vivo. In reality, PEI remains one of those few polymer-based 
platforms most widely explored in clinic (13, 14), including an ongoing phase II trial 
(NCT02806687), with a proven favorable safety profile (NCT01274455) (15). Further, PEI has 
been commonly derivatized with PEG to improve its pharmacokinetic behaviors and/or safety 
profiles as a gene delivery system (9, 16-19). To this end, we have recently demonstrated that 
DNA-loaded nanoparticles (DNA-NP) formulated with an inclusion of densely PEGylated PEI 
(PEG-PEI) provide widespread transgene expression in healthy rat brain while exhibiting good 
in vivo safety profiles, namely brain-penetrating nanoparticles (BPN) (9, 19). However, the 
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finding does not readily ensure their ability to penetrate brain tumor tissues, given that the 
barrier properties of tumor ECM are unlikely analogous to those of normal ECM due to 
significant pathological changes in cellularity and macromolecular compositions in tumors (20). 
In this study, we thus sought to engineer and evaluate PEI-based DNA-NP possessing a 
broader range of surface PEG contents to identify a lead system providing widespread 
transgene expression in brain tumor in vivo. 
Most of the studies developing gene vectors for cancer therapy employ routine sequential 
experimental steps of screening newly designed systems using two-dimensional (2D) cell 
cultures (21-23), followed by in vivo evaluation. However, conventional 2D cultures are limited in 
recapitulating the highly complex and heterogeneous nature of tumors established in living 
organisms, including humans (24, 25). Indeed, virtually no correlation has been observed 
between performances of gene vectors in 2D cultures versus in animals in a recent study (26). 
Alternatively, three-dimensional (3D) models of multicellular tumor spheroids mimic several 
features found in tumors in vivo, including but not limited to dense ECM formation (27, 28) and 
induction of hypoxia and necrosis (29, 30), thereby providing a reliable surrogate for screening 
gene vectors, particularly in terms of predicting their in vivo behaviors (31). Thus, we here 
evaluate and compare performances of newly designed PEI-based DNA-NP in a 3D spheroid 
model as well as in an orthotopically-established rat glioma.   
2. Materials and methods 
2.1 DNA-NP formulation and characterization 
2.1.1 Polymer preparation 
     Methoxy PEG N-hydroxysuccinimide (mPEG-NHS, 5 kDa, Sigma-Aldrich, St. Louis, MO) 
was conjugated to 25 kDa branched PEI (Sigma-Aldrich) to yield PEG-PEI copolymers, as 
previously described (9, 16). Briefly, PEI was dissolved in ultrapure distilled water, pH was 
adjusted to 7.5–8.0 and then mPEG-NHS was added to the PEI solution at various molar ratios, 
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followed by an overnight reaction at 4 °C under a constant mixing condition. The resultant 
polymer solution was dialyzed extensively against ultrapure distilled water for 3 days at a 
molecular weight cut-off (MWCO) of 50,000 kDa (Spectrum Laboratories, Inc., Rancho 
Dominguez, CA) and subsequently lyophilized. Nuclear magnetic resonance (NMR) analysis 
was conducted to confirm PEG to PEI molar ratios of 8, 30, 50, 60, and 85. 1H NMR (500 MHz, 
D2O): δ 2.48-3.20 (br, CH2CH2NH), 3.62-3.72 (br, CH2CH2O). The lyophilized polymers were 
dissolved in ultrapure distilled water with a pH adjustment to ~6.5 - 7 at 30 mg/ml and stored at 
4 °C until use. 
2.1.2 DNA-NP formulation  
     The luciferase-expressing plasmids driven by the short-acting cytomegalovirus (CMV) 
promoter (i.e. pd1GL3-RL) was a kind gift from Professor Alexander M. Klibanov (M.I.T). The 
ZsGreen- and green-fluorescent protein (GFP)-expressing plasmids driven by the CMV 
promoter were purchased from Clontech Laboratories Inc. (Mountainview, CA). The luciferase- 
and mCherry-expressing plasmids driven by human β-actin promoter (i.e. pBAL and pBACH, 
respectively) were produced and provided by Copernicus Therapeutics (Cleveland, OH). 
Plasmids were propagated and purified, as previously described (16, 32). Briefly, plasmids were 
transformed into E. coli DH5α competent bacterial cells using a heat shock method, and 
following the bacterial expansion in LB media, plasmids were purified using EndoFree Plasmid 
Giga Kit (QIAGEN, Valencia, CA), as per manufacturer's protocol. Mirus Label IT Tracker 
Intracellular Nucleic Acid Localization Kit (MirusBio, Madison, WI) was used to fluorescently tag 
plasmids with Cy5 fluorophores. DNA-NP were formed by dropwise addition of 10 volumes of 
labeled or unlabeled plasmids (0.2 mg/mL) to 1 volume of a swirling polymer solution. All DNA-
NP were prepared at an optimized nitrogen to phosphate (N/P) ratio of 6. For the formulation of 
conventional PEGylated nanoparticles (CPN), PEG-PEI copolymers prepared at a PEG to PEI 
molar ratio of 8 alone were used to condense plasmids. BPN formulations were engineered by 
condensation of plasmids by a mixture of non-PEGylated PEI (25%) and PEG-PEI (75%) 
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synthesized at higher PEG to PEI molar ratios of 30 and 50. For microscopic observations, Cy5-
labeled plasmids were used to assemble fluorescently-labeled DNA-NP. The plasmid/polymer 
solution was incubated for 30 minutes at room temperature to spontaneously form DNA-NP. 
DNA-NP were washed twice with 3 volumes of ultrapure distilled water, and re-concentrated to 
1 mg/ml using Amicon Ultra Centrifugal Filters (100,000 MWCO; Millipore Corp., Billerica, MA). 
Plasmid concentration was determined via absorbance at 260 nm using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE).  
2.1.3 Physicochemical characterization of DNA-NP 
     The hydrodynamic diameters as well as polydispersity index (PDI) and ζ-potentials of DNA-
NP were measured by dynamic light scattering (DLS) and laser Doppler anemometry, 
respectively, in 10 mM NaCl solution at pH 7.0 using a Nanosizer ZS90 (Malvern Instruments, 
Southborough, MA). The size and morphology of DNA-NP were also confirmed by transmission 
electron microscopy (TEM; Hitachi H7600, Japan). The DNA complexation was confirmed by 
conventional agarose gel-based electrophoretic analysis. The colloidal stability was assessed 
by monitoring the change in hydrodynamic diameters and PDI in artificial cerebrospinal fluid 
(aCSF, Harvard Apparatus, Holliston, MA) over time at 37 °C via DLS. Number of plasmid 
copies in each DNA-NP was CICS, as previously reported (33). Briefly, DNA-NP carrying Cy5-
labeled plasmids were passed through a custom-made polydimethylsiloxane-based microfluidic 
device to spatially constrict particles to ensure single particle detection using a HeNe laser. The 
fluorescence data was collected with DNA-NP immediately after the preparation or 4 hours after 
an incubation in aCSF. Then fluorescence readings were detected and analyzed using Labview 
interface (National Instruments, Austin, TX) and a MATLAB script, respectively, to determine the 
number of plasmid copies for each DNA-NP population. Of note, quenching artifact was 
carefully assessed using a particle series of increasing ratio of labeled DNA to unlabeled free-




2.2 In vitro experiments in 2D cell cultures 
2.2.1 Cell culture  
     Highly aggressive rat glioma F98 cells (ATCC, Manassas, VA) were cultured in Dulbecco's 
modified Eagle's medium (DMEM, Invitrogen Corp., Carlsbad, CA) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS; Invitrogen Corp.) and 1% penicillin/streptomycin (P/S; 
Invitrogen Corp.). All the following in vitro studies were conducted when cells reached 70% - 
80% confluency in respective plates. 
2.2.2 Cell viability  
     Cells were seeded onto 96-well plates at an initial density of 5,000 cells/well and grown 
overnight at 37 °C. Cells were treated with various DNA-NP at a wide range of plasmid doses 
for 48 hours at 37 °C. Cell viability was then assessed using Dojindo cell counting kit-8 (Dojindo 
Molecular Technologies, Inc., Rockville, MD). Absorbance at 450 nm was measured 
spectrophotometrically using a Synergy Mx Multi-Mode Microplate Reader (Biotek, Instruments 
Inc. Winooski, VT), and cell viability was determined by normalizing the readouts to absorbance 
measured with untreated control cells. 
2.2.3 Cellular uptake 
     Cells were seeded onto 6-well plates at an initial density of 200,000 cells/well and grown 
overnight at 37 °C. Cells were treated with various DNA-NP carrying Cy5-labeled plasmids (5 
μg DNA/well) and after 5 hours of incubation, the media was removed. Cells were then 
thoroughly washed with 1X phosphate buffered saline (PBS) and trypsinized. Flow cytometry 
was conducted to quantify the cellular uptake of DNA-NP using a Sony Cell Sorter SH800 
(Sony, San Jose, CA), followed by data analyzed with a FlowJo software (FlowJo LLC, Ashland, 
OR).  
2.2.4 Transgene expression 
     Cells were seeded at an initial density of 50,000 cells/well onto 24-well plates and grown 
overnight at 37 °C. Cells were then treated with various DNA-NP carrying luciferase-expressing 
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plasmids (i.e. pd1GL3-RL) at a plasmid concentration of 1 μg/well, and the culture media was 
replaced with fresh media 5 hours after the incubation. After 48 hours of additional incubation, 
media was removed and 0.5 ml of 1X Reporter Lysis Buffer (Promega, Madison, WI) was 
added. Subsequently, cells were subjected to three freeze-and-thaw cycles to achieve complete 
lysis followed by the collection of supernatants by centrifugation. Luciferase activity was 
measured in relative light units (RLU) using a standard Luciferase Assay Kit (Promega) and a 
20/20n luminometer (Turner Biosystems, Sunnyvale, CA). The RLU values were normalized to 
the total protein content measured by a Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo 
scientific, Rockford, IL). 
     In parallel, transgene expression was also evaluated by confocal microscopy. Cells were 
seeded in 35 mm glass-bottom dishes of which surfaces were coated with poly-D-lysine 
(MatTek Corporation, Ashland, MA) at an initial density of 30,000 cells/dish and grown overnight 
at 37 °C. Cells were then treated with various DNA-NP carrying ZsGreen- or GFP-expressing 
plasmids at a plasmid concentration of 1 μg/dish, and the culture media was replaced with fresh 
media 5 hours after the incubation. After 48 hours of additional incubation, one drop of 
NucBlue™ Live Cell Stain (4’,6-diamidino-2-phenylindole or DAPI; Invitrogen Corp.) was added 
to each dish to visualize cell nuclei. Then fluorescence was captured from DAPI and ZsGreen or 
GFP, respectively, using an LSM 710 confocal microscope (Carl Zeiss; Hertfordshire, UK) under 
20X magnification. Subsequently, images were analyzed using an ImageJ software (NIH, 
Bethesda, MD).  
2.3 In vitro experiments in 3D multicellular tumor spheroids 
2.3.3 Preparation of spheroids 
     3D tumor spheroids were established by the hanging-drop method, which cultivates the cells 
within an agarose matrix, blended with a house-made spheroid media, and then transferred to 
regular DMEM (see Figure 2.1 for various types of cell culture). The spheroid media was 
prepared by dissolving autoclaved methylcellulose (Sigma-Aldrich) at 2.4% (w/v) in preheated 
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(60 °C), serum-free DMEM followed by dilution with an equivolume of DMEM supplemented with 
10% FBS and an overnight stirring at 4 °C. The solution was then centrifuged at 5,000 xg for 2 
hours at 4 °C to precipitate undissolved methylcellulose and the supernatant stored at 4 °C until 
use. To form each spheroid, we cultured 5,000 cells, either F98 glioma cells or F98 cells 
engineered to constitutively express a red fluorescent protein, mKate (F98-mKate; provided Dr. 
Surojit Sur; Johns Hopkins University), in 20 µL spheroid media on the lid of a petri-dish. 
Spheroids were then grown upside down by covering a PBS-filled/moisturized petri-dish with the 
cell-seeded lid for 2 days. Finally, spheroids were transferred onto a sterile U-bottom 96-well 
plate (CELLSTAR®; Sigma-Aldrich) along with DMEM and incubated at 37⁰C for 24 hours prior 
to their use for subsequent experiments.     
 
2.3.2 Distribution of DNA-NP in 3D spheroids 
     To evaluate the ability of DNA-NP to penetrate 3D tumor spheroids, we treated F98-mKate-
based spheroids with various DNA-NP carrying Cy5-labeled plasmids (1 μg plasmids/spheroid). 
The media was removed 5 hours after the incubation and replaced with the background-
minimizing FluoroBrite DMEM. Subsequently, spheroids were fixed with 4% formaldehyde, 
washed with PBS, embedded in Tissue-Tek® optimal cutting temperature compound (Sakura 
Finetek, Torrance, CA) and sectioned into 20 μm-thick slices using Leica CM 1905 cryostat 
(Leica Biosystems, Buffalo Grove, IL).  Slices were imaged for the fluorescence originated from 
F98 glioma cells (i.e. mKate) and DNA-NP (i.e. Cy5) using an LSM 710 confocal microscope 
Figure 2.1: Schematic diagrams of various common methods of cell culture. (A) Traditional 2D 
monolayer cell culture, (B) 3D cell spheroids grown on matrix, (C) Cells embedded within matrix, or 
(D) Scaffold-free cell spheroids in suspension. Reproduced from Edmondson R. et al. 2014 with 
permission from Mary Ann Liebert, Inc. 
A          B        C                      D                                      
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under 10X magnification. The radial distribution profile of DNA-NP was obtained by measuring 
the mean fluorescence intensity throughout the radial coordinates from the edge to the core of 
the spheroid using an ImageJ software, as previously described (34).  
2.3.3 Transgene expression by DNA-NP in 3D spheroids 
     F98-based spheroids were treated with various DNA-NP carrying ZsGreen-expressing 
plasmids (1 μg plasmids/spheroid) to evaluate the ability of DNA-NP to mediate transgene 
expression in spheroids. At 5-hour post-incubation, the culture media was replaced by fresh 
FluoroBrite DMEM. After 48 hours of additional incubation, the spheroids were transferred on to 
custom-made gel-wells. To prepare a stock gel media, low gelling temperature agarose (Sigma-
Aldrich) was dissolved at 5% (w/v) in sterile PBS and subsequently autoclaved. The working gel 
media was then made by diluting the stock with FluoroBrite DMEM to reach the final agarose 
concentration of 0.5% (w/v). Subsequently, a 4-well Millicell EZ slide (Millipore Corp) was filled 
with the working gel media and spheroids were carefully placed in each well. Fluorescence 
images were then captured using an LSM 710 confocal microscope under 10X magnification 
and analyzed for spheroid area-normalized mean fluorescence intensity using an ImageJ 
software.  
2.4 Multiple particle tracking – ex vivo diffusion of DNA-NP in rat brain 
      Multiple particle tracking (MPT) experiments were conducted to quantify the diffusion rates 
of various DNA-NP carrying Cy5-labeled plasmids in healthy rat brain parenchyma ex vivo, as 
previously reported (9, 16). Briefly, whole brain tissues were harvested from 6-to-8-week-old 
female Fischer 344 rats (Harlan Laboratories, Frederick, MD) and incubated in aCSF on ice for 
10 minutes. The brain tissues were then sliced using a Zivic brain matrix slicer (Zivic 
Instruments, Pittsburgh, PA) and the resultant 1.5-mm coronal slices were placed on custom-
made slides. Subsequently, we injected 0.5 μL of DNA-NP solution at a plasmid concentration 
of 2 μg/mL into the cerebral cortex at a depth of 1 mm using a Neuros syringe (50 μL; Hamilton, 
Reno, NV) mounted on an ultra-precise small-animal stereotactic frame (Stoelting Co., Wood 
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Dale, IL). Trajectories of DNA-NP were recorded over 20 seconds at an exposure time of 66.7 
milliseconds (i.e. 15 fames/s) by an Evolve 512 EMCCD camera (Photometrics, Tucson, AZ) 
mounted on an inverted epifluorescence microscope (Axio Observer D1; Carl Zeiss, 
Hertfordshire, UK) equipped with a 100X/1.46 NA oil-immersion objective. Movies were then 
analyzed with a custom-made automated particle tracking MATLAB script to extract x, y-
coordinates of DNA-NP centroids over time from which the mean square displacement (MSD) 
values of individual DNA-NP were calculated as a function of timescale (35). Median MSD was 
determined based on the measured MSD values of individual DNA-NP at a timescale of 1 
second, at which both static and dynamic errors are minimized in MPT experiments (35). 
2.5 Animal studies 
     We used 6-to-8-week-old female Fischer 344 rats for the assessment of in vivo gene transfer 
efficacy of various DNA-NP. Animals were treated in accordance with the guidelines and 
policies of the Johns Hopkins University Animal Care and Use Committee. Surgical procedures 
were performed using standard sterile surgical techniques. Animals were anesthetized using a 
mixture of 75 mg/kg ketamine and 7.5 mg/kg xylazine, as previously described (36). A midline 
scalp incision was made to expose the coronal and sagittal sutures and a burr whole was drilled 
3 mm lateral to the sagittal suture and 0.5 mm posterior to the bregma. Following the tumor cell 
inoculation or DNA-NP administration, the skin was sealed using biodegradable sutures 
(Polysorb™ Braided Absorbable Sutures 5–0) and bacitracin was applied. 
2.5.3 Orthotopic tumor cell inoculation 
     Orthotopic tumor cell inoculation was performed, as previously described (36). Briefly, 
100,000 cells, either F98 or F98-mKate cells, were administered in 10 µL of DMEM over 5 
minutes at a depth of 3.5 mm using a Neuros Syringe mounted on an ultra-precise small-animal 
stereotactic frame. Of note, we inoculated rat brains with a high numbers of tumor cells, relevant 
to clinical translation (37, 38), to establish a model mimicking malignant gliomas characterized 




2.5.4 Intracranial administration - CED 
      To assess the distribution of transgene expression, various DNA-NP carrying ZsGreen- or 
luciferase-expressing plasmids were intracranially administered via CED, as previously 
described (9, 10). Briefly, a Neuros syringe connected to a 33-gauge needle was filled with 20 
μL of DNA-NP solution at a plasmid concentration of 1 mg/mL and lowered to a depth of 3.5 or 
2.5 mm of a healthy or an orthotopic tumor-bearing rat brain, targeting the striatum or the tumor 
core, respectively. DNA-NP solution was then infused at a rate of 0.33 μL/min as controlled by a 
Chemyx Nanojet Injector Module (Chemyx, Stafford, TX).  
2.5.5 Distribution and overall level of transgene expression  
     For assessing the distribution of transgene expression, brain tissues of rats received DNA-
NP carrying ZsGreen-expressing plasmids were harvested 48 hours after the administration and 
subsequently fixed with 4% formaldehyde. Tissues were then sectioned using a Leica CM 1905 
cryostat into 100 or 50 μm coronal slices for healthy or tumor-bearing rats at ± 3 mm of the 
infusion plane in striatum or until the tumor tissue was no longer visible, respectively. Slices of 
F98-based orthotopic tumor tissues were stained with DAPI (Molecular Probes, Eugene, OR) to 
visualize tumor cell nuclei. All fluorescence images were taken using an LSM 710 confocal 
microscope under 5X, 20X and/or 40X magnification. We carefully optimized the settings to 
avoid background fluorescence based on the microscopy of untreated control rat brains. The 
volume of transgene expression was quantified using a custom-made MATLAB script that 
subtracted background fluorescence by Otsu’s method of thresholding (39, 40). The area of 
DNA-NP spreading in each slice was integrated to calculate the total volume of transgene 
expression. To reconstruct 3D-rendered imaginings, we stacked and aligned the acquired 
images using Metamorph ® Microscopy Automation & Image Analysis Software (Molecular 
Devices, CA). Finally, we used an Imaris Software (Bitplane, CT) to create 3D isosurfaces of the 
reconstructed images.  
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The kinetics of transgene expression was also determined based on the distribution of 
transgene expression over time. For the assessment of a short- and a long-term transgene 
expression, animals were treated with a BPN formulation carrying ZsGreen- and mCherry-
expressing plasmids driven by CMV and human β-actin promoters, respectively. In parallel, we 
determine the volume of transgene expression mediated by a BPN formulation stored at 4 °C for 
one month, following a routine physicochemical characterization as described above. 
To quantify the overall level of transgene expression, we treated rats using the identical 
dosing method applied to the distribution study but with various DNA-NP carrying luciferase-
expressing plasmids (i.e. pBAL). Seven days after the administration, tissues were harvested 
and subjected to homogenate-based luciferase assay using a standard Luciferase Assay Kit 
and a 20/20n luminometer. The RLU values were normalized to the total protein content 
measured by BCA protein assay. 
2.5.6 Immunofluorescence 
To assess the transgene expression in different cell types, animals bearing orthotopic F98-
mKate-based tumor were treated with a BPN formulation carrying ZsGreen-expressing plasmids 
as described above. Two days after the administration, brain tissues were harvested, sectioned 
and subjected to immunochemistry. Specifically, astrocytes and microglial cells were 
immunostained by antibodies against GFAP (Abcam, Cambridge, UK) and Iba1 (Wako Chem 
USA Corp., Richmond, VA). Images were taken using an LSM 710 confocal microscope under 
20X and/or 40X magnification. The transgene expression in F98-mKate glioma and microglial 
cells was quantified using an ImageJ software based on the co-localization of different 
fluorescence. At least three representative fields of view from at least three different coronal 
sections were used for the analysis. 
2.6 Statistical analysis 
Statistical analysis between two groups was conducted using a two-tailed Student's t-test 
assuming unequal variances. If multiple comparisons were involved, one-way analysis of 
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variance (ANOVA), followed by Sidak's multiple comparisons test, was employed, using 
GraphPad Software (GraphPad Software Inc., La Jolla, CA). Differences were determined to be 
statistically significant at p < 0.05. 
3. Results and discussion 
3.1 Formulation and characterization of DNA-NP  
We first engineered three PEI-based DNA-NP possessing different surface PEG contents. 
CPN were formulated by condensing plasmids solely with PEG-PEI synthesized at a moderate 
PEG to PEI ratio of 8, as previously reported (9). In parallel, we engineered two additional DNA-
NP with greater surface PEG contents using a method that we have previously developed to 
endow gene vectors with excellent compaction and colloidal stability in physiological conditions 
while providing capability to efficiently penetrate healthy brain parenchyma, BPN (9). 
Specifically, a blend of non-PEGylated PEI and PEG-PEI synthesized at a high PEG to PEI ratio 
of 30 or 50 was used to condense plasmids to yield BPNL (i.e. lower PEG BPN) or BPNH (i.e. 
higher PEG BPN), respectively (Figure 2.2). Of note, BPNL is a close relative to a PEI-based 
DNA-NP that we have confirmed for efficient penetration through healthy rat brain tissues ex 
vivo and in vivo in our previous study (9). We here hypothesized that a greater PEGylation, 
unless interferes with a capacity of PEI to form stable particles, might further enhance the ability 
of the resultant DNA-NP to percolate not only in healthy brain parenchyma but also in brain 
tumor tissues.  
We found that all three freshly prepared DNA-NP exhibited similarly small sizes (i.e. ~50 nm 
in hydrodynamic diameters) and excellent PDI values (≤ 0.20) (Table 2.1). On the other hand, 
the ζ-potential, an indicative of particle surface charge, decreased from positive towards neutral 
values with increased PEG contents (i.e. 18.0 ± 0.2, 7.0 ± 0.3 and 2.0 ± 0.1 mV for CPN, BPNL 
and BPNH, respectively; Table 2.1), indicating that the otherwise cationic DNA-NP surfaces 
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were effectively masked by PEG corona, particularly more so for BPNH that showed near-
neutral ζ-potential values.   
    
 
The particle morphology was confirmed by TEM to be ~50 nm spheres regardless of 
PEG contents (Figure 2.3A-C), in consistent with the measured hydrodynamic diameters (Table 
2.1). We found that BPN candidates formulated with an inclusion of PEG-PEI synthesized at 
even higher PEG to PEI ratios of 60 and 85 exhibited similar physiochemical properties as 
BPNH (Table 2.2), and thus excluded in subsequent evaluations. We then verified robust DNA 
compaction by all three different DNA-NP via a conventional agarose-gel migration assay; 
PEG 
Figure 2.2: Schematic demonstrating DNA-NP possessing different surface PEG coverage.  
PEI (yellow)-based DNA-NP with varying surface PEG (red) densities are formulated by compacting plasmid 
DNA (dark blue) with PEGylated PEI alone (i.e. conventional PEGylation) or a blend of non-PEGylated and 
PEGylated PEI, including (A) conventionally PEGylated DNA-NP (CPN) and brain-penetrating DNA-NP 
possessing (B) a lower (BPNL) and (C) a higher (BPNH) PEG contents. 
 










 SEM at 12 hours 
in aCSF (nm)c
PDI 
at 12 hours 
in aCSFc
CPN 50 ± 1 0.16  18.0  ± 0.2 212 ± 3 0.17
BPNL 49 ± 1 0.19 7.0 ± 0.3 67 ± 6 0.16
BPNH 48 ± 5 0.20 2.0 ± 0.1 56 ± 3 0.15
a 
Hydrodynamic diameter and polydispersity index (PDI) were measured by dynamic light scattering (DLS) 
in 10 mM NaCl. Mean ± SEM (n ≥ 3).  
b 
ζ-potential was measured by laser Doppler anemometry in 10mM NaCl at pH 7.0. Mean ± SEM (n ≥ 3).  
c 
Hydrodynamic diameter and PDI were measured by DLS following a 12-hour incubation in aCSF at 37⁰C. 
Table 2.1: Physicochemical properties of DNA-NP. 
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however, CPN, regardless of its lower PEG content, showed a brighter signal in the well 
compared to BPNL and BPNH, suggesting that an inclusion of non-PEGylated PEI in the blended 
BPN formulations might have enhanced their abilities to compact the plasmid payloads (Figure 
2.3D).  
In addition to these conventional physicochemical characterization, we conducted an 
additional analysis to quantify the average number of plasmid copies per different DNA-NP 
using cylindrical illumination confocal spectroscopy (CICS) technique (33). We found that each 
CPN contained an average of approximately four plasmid copies, whereas BPNL and BPNH 
packaged roughly two copies on average (Figure 2.3F). The finding suggests that double the 
amount (i.e. number of particles) of both BPN formulations will be administered compared to 
 
CPN at a fixed treatment dose of plasmids; this may be beneficial for enhancing gene 
transfer efficacy given a prior observation that the total amount of plasmid-containing particles 
































































F re s h
A m o u n t o f  p la s m id
D ia m e te r  (n m )

















































* * * * * *
4  h o u rs  in  a C S F
A m o u n t o f  p la s m id
D ia m e te r  (n m )
E                                   F                                   G 
Figure 2.3: Physicochemical properties and stability of DNA-NP. Transmission electron microscopy 
images of (A) CPN, (B) BPNL, and (C) BPNH freshly made in ultrapure water. Scale bar = 400 nm. (D) 
Compaction of plasmids in DNA-NP shown by electrophoresis: I) free DNA, II) CPN, III) BPNL, IV) BPNH. 
Number of plasmids in each DNA-NP and hydrodynamic diameter of DNA-NP when (E) freshly made in 
water and (F) when incubated in aCSF for 4 hours. (G) Change in hydrodynamic diameters over 12 hours 
in aCSF at 37oC measured by DLS. ***denotes a statistically significant difference of CPN compared to 
BPNL and BPNH (p < 0.001).  
 
A                        B                       C                       D 
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rather than the overall plasmid quantity is the limiting factor for PEI-mediated transfection (41). 
We next assessed the hydrodynamic diameters and plasmid copies per particle of different 
DNA-NP following a 4-hour incubation in aCSF at 37⁰C to predict potential alteration of particle 
properties in the physiological brain environment. We found that while both BPN formulations 
retained their hydrodynamic diameters in aCSF, the size of CPN incremented near to ~150 nm 
(Figure 2.3E) and continue to grow afterward, suggesting that CPN would be unlikely to 
efficiently penetrate brain tissues due to large particle size as well as positively charged particle 
surfaces. In contrast, the average number of plasmid copies per particle did not change upon 
aCSF incubation regardless of the DNA-NP type. The finding reveals that the increase in CPN 
size in aCSF is most likely attributed to particle swelling rather than aggregation, providing an 
additional evidence that inclusion of non-PEGylated PEI in the blended BPN formulations 
endowed DNA-NP with an enhanced plasmid compaction stability.   
 
3.2 Transfection efficiency of DNA-NP in 2D culture versus 3D spheroid model 
We initially sought to investigate the in vitro transfection efficiency of different DNA-NP 
formulated to carry the most widely used reporter, GFP. However, evidences suggest that 
immunogenicity and cytotoxicity of GFP potentially confound the interpretation of in vitro and/or 
vivo transfection data (42-44). Therefore, we compared the cytotoxicity and transfection 






ζ-Potential  SEM 
(mV)b
BPNH65:1 43 ± 4 0.20  2.2  ± 10
BPNH80:1 50 ± 9 0.22 2.1 ± 2.6
Table 2.2: Physicochemical properties of DNA-BPNH at higher PEG:PEI ratios. 
a 
Hydrodynamic diameter and polydispersity index (PDI) were measured by dynamic light scattering (DLS) 
in 10mM NaCl at pH 7.0. Mean ± SEM (n ≥ 3).  
b 
ζ-potential was measured by laser Doppler anemometry in 10mM NaCl at pH 7.0. Mean ± SEM (n ≥ 3).  
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rat glioma cells following the treatment of cells with lipofectamine carrying respective plasmids 
at an identical dose. We found that GFP exhibited greater (i.e. ~3-fold) toxicity and lower (i.e. 
~5-fold) transfection efficiency than ZsGreen (Figure 2.4), in agreement with previous reports 
(45, 46). We thus pursed the following studies with different PEI-based DNA-NP, including CPN, 
BPNL and BPNH, carrying ZsGreen-expressing plasmids.  
        
We first evaluated the cytotoxicity of DNA-NP at various concentrations of plasmid 
payloads following 48 hours of incubation. All DNA-NP showed comparably good cell viability 
(i.e. ~100%) at the plasmid concentrations of 1 and 5 µg/mL, but CPN, but not BPN 
formulations, resulted in over 40% cell death at 10 μg/mL (p < 0.001) (Figure 2.5A). However, 
we note that the 10 µg/mL plasmid concentration is markedly great than conventional working 
concentrations for in vitro transfection experiments.  
We then assessed in vitro cellular uptake and transfection efficiency of DNA-NP carrying 
Cy5-labeled and unlabeled plasmids, respectively, using an F98-based 2D cell culture. The 
percentage of cells that took up detectable amounts of Cy5-labeled plasmid payloads were all 
~100% regardless of the type of DNA-NP (Figure 2.5B), in agreement with our and others’ 
observations that PEGylation does not completely block individual cells to engulf small 
nanoparticles (9, 10, 47, 48). However, the amounts of internalized DNA-NP per cell, as 
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Figure 2.4: Relative in vitro transgene expression and toxicity of ZsGreen and GFP 
in F98 cells. (A) Representative confocal images at 20X magnification showing ZsGreen 
(left) and GFP (right) transgene expression 2 days after the transfection with 
lipofectamine. Scale bar = 250 µm. (B) Quantitative analysis of transgene expression and 
toxicity as measured by mean fluorescence intensity and cell viability, respectively. 




indicated by fluorescence intensity, were significantly lower for BPNL and BPNH in comparison 
to CPN (p <0.001; Figure 2.5B). Considering that each BPN carries 2 copies of DNA compared 
to 4 for each CPN, it seems to indicate similar or only slightly low uptake efficiency per 
nanoparticle, although potential impacts of dense PEG on other intracellular processes cannot 
be fully excluded (49). Accordingly, in vitro transfection efficiencies of BPNL and BPNH, as 
confirmed by confocal microscopy and homogenate-based luminescence assay (p < 0.001), 
were lower than those of CPN (Figure 2.5C-D). 
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Figure 2.5: Cell viability, cell uptake and transfection in F98-based 2D cell cultures. (A) Cell 
viability measured 48 hours after NP-treatment at varying plasmid concentrations, in comparison to 
an untreated control. #denotes statistically significant differences in comparison to other 





10 µg/ml (p < 0.001). (B) Flow cytometry analysis of percentage cell uptake and median fluorescence 
intensity (i.e. degree of cell uptake per cell) 5 hours after NP-treatment with different DNA-NP. (C) 
Representative confocal images at 20X magnification showing ZsGreen reporter transgene 
expression (green) 48 hours after NP-treatment carrying ZsGreen-expressing plasmids. Cell nuclei 
are stained by DAPI (blue). Scale bar = 100 µm. (D) In vitro luciferase transgene expression 48 hours 
after NP-treatment carrying luciferase-expressing plasmids. Data represented as mean ± SEM. 








Importantly, 2D cell cultures, due in part to the absence of extracellular components, do not 
provide a reliable model for predicting in vivo performances of gene vectors. We thus 
investigated in vitro behaviors of DNA-NP in an F98-based 3D model of multicellular tumor 
spheroid that better recapitulates architecture and biology of solid tumors observed in vivo (50). 
In particular, 3D spheroid models simulate an ECM-filled intercellular permeability barrier (50-
53), and thus serve as an excellent model to evaluate the penetration of gene vectors through 
solid tumor tissues (54). To this end, we constructed a 3D spheroid model with F98-mKate cells 
and assessed distribution of different DNA-NP carrying Cy5-labeled plasmids. As shown by 
representative confocal images, DNA-NP with denser surface PEG coronas exhibited greater 
inward penetration compared to those with less PEG contents (BPNH > BPNL > CPN; Figure 
2.6A).    
Quantitatively, BPNH showed the greatest spheroid penetration in the radial profile from the 
edge (coordinate 0) to the core (coordinate 1) of the spheroid, followed by the BPNL and CPN 
(Figure 2.6B). We then evaluated the distribution and level of transgene expression following 
the treatment of the spheroids with DNA-NP carrying ZsGreen-expressing plasmids. Similar to 
the vector distribution study (Figure 2.6A), representative confocal images revealed a greatest 
distribution of transgene expression by BPNH compared BPNL and CPN with CPN exhibiting a 
weakest distribution (Figure 2.6C). In addition, BPNH, but BPNL, showed significantly greater 
level of transgene expression, as measured by mean fluorescence intensity, compared to CPN 
(p <0.05; Figure 2.6D). While the average fluorescence intensity of BPNL was ~4-fold greater 
than that of CPN, statistical significance was not achieved presumably due to variability of the 
transgene expression mediated by BPNL in different individual spheroids (Figure 2.6D). The 
findings here underscore that, in contrast to the observations with 2D cultures (Figure 2.5), 
DNA-NP with greater surface PEG coverage provides superior transgene expression compared 
to those with lesser PEG, due to the ability to efficiently penetrate the extracellular barrier 




3.3 Ex vivo diffusion of DNA-NP in rodent brain tissues 
We have previously demonstrated that diffusion rates of nanoparticles, measured by MPT, 
in brain tissues ex vivo reliably predict their spread in brain parenchyma in vivo (5, 8-10). We 
thus conducted MPT experiments to confirm that a greater surface PEG coverage resulted in 
enhanced brain penetration by DNA-NP. Specifically, DNA-NP carrying Cy5-labled plasmids 
were injected into a freshly harvested healthy rat brain tissue and their diffusion was monitored 
over a time period of 20 seconds. As evidenced by the highly constrained trajectory, CPN were 
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Figure 2.6: In vitro DNA-NP distribution and transgene expression in F98-based 3D spheroids. 
(A) Representative images showing F98 tumor spheroids (red; mKate) 5 hours after treatment with 
DNA-NP (cyan; Cy5). Scale bar = 250 µm. (B) Quantification of radial distribution of DNA-NP within 
the spheroids. The coordinates 0 and 1 indicate the spheroid edge and core, respectively. (C) 
Representative reporter transgene expression (green; ZsGreen) by DNA-NP carrying ZsGreen-
expressing plasmids 48 hours after NP-treatment. (D) Quantification of ZsGreen transgene 




immobilized in the brain parenchyma. In contrast, BPNL and BPNH demonstrated relatively 
unhindered motions, leading to trajectories that span several microns in distance (Figure 2.7A). 
We then quantified their diffusion rates of DNA-NP by measuring the MSD; which represents an 
averaged square of distances traveled by individual particles within a given time interval and 
thus MSD values are directly proportional to respective particle diffusion rates.(55) In consistent 
with our prior observation (9), BPNL exhibited significantly greater MSD values compared to 
CPN (p < 0.001), but we found here that increasing the surface PEG coverage further enhanced 
the ability of PEI-based DNA-NP to penetrate brain tissue ex vivo (i.e. BPNH > BPNL > CPN; 
Figure 2.7B). We also note that BPNH exhibited more uniform high MSD values than BPNL, 
suggesting that BPNH may provide a more consistent ability to penetrate through the highly 
heterogeneous tumor microenvironment.   
 
3.4 Transgene expression mediated by DNA-NP in healthy brain parenchyma   
We next investigated whether ex vivo diffusion behaviors of DNA-NP translated to their in 
vivo distribution patterns in healthy rat brain. Different DNA-NP carrying ZsGreen-expressing 
plasmids were administered into the rat striatum via CED that has been clinically applied to 
enhance the therapeutic distribution within brain by creating a continuous pressure-driven bulk 
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Figure 2.7: Ex vivo diffusion of different DNA-NP in rat brain tissues. (A) Representative 
trajectories of DNA-NP in rat brain tissue over 20 seconds. Scale bar = 1 µm. (B) Logarithms of 
median mean square displacements (MSD) of DNA-NP at a time scale of 1 second. Data 
represent 5 independent experiments with n ≥ 200 particles tracked for each experiment. 
Differences are statistically significant as indicated (*p < 0.05; ***p < 0.001).  










flow (39, 56). Transgene expression was then assessed 48 hours after the treatment. The 3D 
reconstruction of confocal images of serial coronal sections of rat brains revealed enhanced 
volumes of transgene expression when rats were treated with DNA-NP possessing greater 
surface PEG coverage (Figure 2.8A). The transgene expression mediated by CPN was confined 
to the site of administration despite the pressure gradient provided by CED. Inability of 
conventional cationic gene vectors to provide widespread transgene expression regardless of 
CED may have attributed to a limited success in a phase I/II clinical trial in which patients with 
glioblastoma received non-PEGylated DNA-NP formulated with cationic lipids via CED (57, 58). 
In agreement with our previous observation (9), BPNL exhibited significantly greater volumetric 
distribution of transgene expression than CPN (p < 0.01), but importantly, BPNH, mostly likely 
due to its superior ability to penetrate the brain parenchyma (Figure 2.8), roughly doubled the 
transfected volume on average in the rat striatum compared to BPNL (p < 0.001; Figure 2.8B). In 
parallel, we quantitatively determined the overall levels of transgene expression mediated by 
CED of BPNH, BPNL and CPN carrying luciferase-expressing plasmids, using a homogenate-
based luciferase assay. Like the trend observed with the transfected volume, DNA-NP 
possessing greater surface PEG contents provided greater overall levels of transgene 
expression; BPNH exhibited statistically significant improvements (p < 0.001) with ~20- and 
~210-fold greater luciferase activities in comparison to BPNL and CPN, respectively (Figure 
2.7C). The findings here suggest that the unique ability of BPNH to further increase the 
volumetric distribution of transgene expression over BPNL led to quantum enhancement of the 
overall gene transfer efficacy. Efforts towards greater transfection efficiencies often focus on 
enhancing cellular gene delivery to a specific cell type of interest, but this study provides an 
example underscoring the importance of achieving a greater coverage of transgene expression 
in a target tissue. 
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To evaluate the expression kinetics of BPNH in healthy rat brains, we treated rats via 
CED with BPNH carrying plasmids controlled either by the CMV or by the long-acting human β-
actin promoter. We found that peak volume of transgene expression lasted up to 2 days or 3 
weeks upon a single treatment when regulated by CMV or human β-actin promoter (Figure 2.9), 
respectively, suggesting that the life span of transgene expression mediated by can be tuned by 
a careful selection of a promoter. We also confirmed that BPNH retained the brain-penetrating 
physiochemical properties (i.e. small particle diameters and near-neutral surface charges; Table 
2.3) and the ability to yield widespread transgene expression in rodent striatum at least for 1 
month when stored at 4⁰C (Figure 2.10).   
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B                                      C 
   CPN            BPNL          BPNH 
Figure 2.8: In vivo transgene expression mediated by CED of different DNA-NP carrying 
ZsGreen- or luciferase-expressing plasmids in healthy rat brain tissues. (A) 
Representative isosurface 3D images depicting volumetric distribution of ZsGreen reporter 
transgene expression (green) in healthy rat brains, obtained by stacking multiple sequential 
confocal images 48 hours after NP-treatment carrying ZsGreen-expressing plasmids. Scale 
bar = 1 mm. (B) Volume of ZsGreen transgene expression (n ≥ 6 rats). (C) Overall level of 
luciferase transgene expression (n ≥ 6 rats). Differences are statistically significant as 
indicated (**p < 0.01; ***p < 0.001).  
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A     2 days             7 days            9 days      B 
C    1 week            3 weeks          6 weeks    D 
CMV  
β-actin  
Figure 2.9: Transgene expression kinetics of fluorescent proteins controlled by CMV or β-actin 
promoter in healthy rat brains following CED of BPNH. (A) Representative isosurface 3D images 
depicting volumetric distribution of ZsGreen reporter transgene expression (green) driven by CMV 
promoter in healthy rat brains at varying time points after the administration. (B) Volume of ZsGreen 
transgene expression (n ≥ 3 rats). (C) Representative isosurface 3D images depicting volumetric 
distribution of mCherry reporter transgene expression (red) driven by β-actin promoter in healthy rat 
brains at varying time points after the administration. (D) Volume of mCherry transgene expression (n 
≥ 3 rats). Scale bar = 1 mm. Differences are statistically significant as indicated (*p < 0.05; **p < 0.01; 














Fresh 55 ± 4 0.15 2.1 ± 1.3 
1 month 61 ± 2 0.17 3.2 ± 2.4 
 
Table 2.3: Physicochemical properties of DNA-BPNH stored at 4⁰C for 1 month. 
a Hydrodynamic diameter and polydispersity index (PDI) were measured by dynamic light 
scattering (DLS) in 10mM NaCl at pH 7.0. Mean ± SEM (n ≥ 3).  
b ζ-potential was measured by laser Doppler anemometry in 10mM NaCl at pH 7.0. Mean ± 
SEM (n ≥ 3).  




           
3.5 Transgene expression mediated by DNA-NP in orthotopic brain tumors 
We next evaluated in vivo gene transfer efficacy of BPNH, BPNL and CPN carrying ZsGreen-
expressing plasmids in an orthotopic model of aggressive brain tumor following CED. The 
model was established by intracranial stereotactic inoculation of 1 x 105 F98 cells and a CED 
experiment was conducted 10 days after the inoculation when a large volume (~30 mm3) of 
orthotopic tumor was established in the rat striatum. As shown by representative 3D-
reconstructed images, BPNH exhibited the greatest volumetric distribution of transgene 
expression, followed by BPNL and CPN (Figure 2.11A). The volume of transgene expression 
achieved by BPNH was ~2- and ~3.5-fold greater than BPNL (p < 0.05) and CPN (p < 0.001), 
respectively, in the orthotopic brain tumor (Figure 2.10B). We then quantified the volumetric 
fractions of the orthotopic tumor with reporter transgene expression mediated by different DNA-
NP. The percentages of total tumor volumes exhibited positive reporter transgene expression 
were ~90%, ~65% and ~35% for BPNH, BPNL and CPN, respectively, with statistically significant 
differences between all different DNA-NP groups (Figure 2.11C). Importantly, the finding here is 
in good accordance with our observation with a 3D tumor spheroid model (Figure 2.5) but 



































A     Fresh               1 month        B
   
Figure 2.10: In vivo transgene expression mediated by BPNH carrying ZsGreen-
expressing plasmids, stored at 4⁰C for one month, in healthy rat brains following CED. 
(A) Representative isosurface 3D images depicting volumetric distribution of Zsgreen 
reporter transgene expression (green) in healthy rat brains, obtained by stacking multiple 
sequential confocal images. Scale bar = 1 mm. (B) Volume of Zsgreen transgene expression 
(n ≥ 3 rats). The difference is not statistically significant. 
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opposite to the trend shown in a 2D culture (Figure 2.4). To this end, 3D tumor spheroid models, 
providing good in vivo correlation unlike 2D culture, may serve as a reliable in vitro surrogate to 
screen newly engineered gene vectors prior to their evaluation for in vivo cancer gene delivery.  
 
In this study, we noticed that the volume of transgene expression mediated by identically 
administered DNA-NP was significantly greater in F98-based orthotopic tumor than in healthy 
rat brain (Figure 2.8 and 2.11). This is not readily expected a prior as the high cellularity 
commonly found in tumors would render the intercellular spaces narrower, thereby potentially 
reinforcing the tumor ECM as a steric barrier. We speculate that the greater volumetric 
transgene expression shown in the orthotopic model may be in part attributed to the 
heterogeneous nature of tumor microenvironment (32), specifically the necrotic regions through 
which BPN formulations can spread out relatively unhindered. In addition, the characteristic high 
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Figure 2.11: Transgene expression mediated by CED of different DNA-NP carrying ZsGreen-
expressing plasmids in F98-based orthotopic rat brain tumor tissues. (A) Representative 
isosurface 3D images depicting volumetric distribution of ZsGreen reporter transgene expression 
(green) in orthotopic brain tumors (light blue), obtained by stacking multiple sequential confocal 
images. Scale bar = 1 mm. (B) Volume of transgene expression (n ≥ 4 rats). (C) Percentage of tumor 
volume covered by transgene expression (n ≥ 4 rats). Differences are statistically significant as 




intratumoral pressure (59) may have facilitated outward diffusion of DNA-NP from the core to 
the tumor edge.  
Highly invasive tumor cells that migrate beyond the tumor edge and infiltrate into normal 
brain tissue are responsible for recurrence of malignant gliomas (60). Thus, the unique ability of 
BPNH to efficiently penetrate both normal brain parenchyma and brain tumor tissue may serve 
favorably for this specific application. However, an additional method to confine therapeutic 
transgene expression to tumor cells would be desired, particularly when therapy can exert a 
toxic effect to normal tissues (e.g. cytotoxic genes). 
3.6 In vivo cell tropism of BPNH in orthotopically established malignant glioma 
While we showed robust reporter transgene expression by BPNH in an orthotopically 
established malignant glioma, the tumor volume and edge were estimated based on the high 
tumor-cell cellularity, uncovered by a conventional DAPI staining. Therefore, we established an 
orthotopic model as described above but with F98 cells constitutively expressing fluorescent 
mKate (i.e. F98-mKate) to confirm whether the transgene expression indeed took place in tumor 
cells in vivo. We first determined F98 cells to be the most abundant cells within the 
orthotopically-established tumor tissue (Figure 2.12). Microglial cells were also ubiquitously 
present within the tumor bulk, as expected from their roles in glioma maintenance and 
progression,(61) whereas neuron-supporting astrocytes were rarely found (Figure 2.12).  
     
A   F98 tumor     B   Astrocytes      C   Microglia       D   Overlay        
Figure 2.12: Cell population in an orthotopically established F98 rat tumor tissue. 
Representative 2D confocal images at 20X magnification (tile scan) showing (A) F98 tumor cells 
(red; mKate), (B) astrocytes (magenta; GFPA), (C) microglia (cyan; Iba1) and (D) overlay. Scale 
bar = 100 µm. 
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We then treated rats harboring orthotopic mKate-expressing F98 tumor with BPNH 
carrying ZsGreen-expressing plasmids via CED and evaluated relative transgene expression in 
those two cells most highly prevalent in the tumor, including F98 and microglial cells. We found 
that ~90% and ~30% of F98 and microglial cells, respectively, were positive to BPNH-mediated 
ZsGreen transgene expression, as determined by image-based analysis of randomly selected 
confocal image fields (Figure 2.13). The BPNH is not specifically designed to preferentially target 
cancer cells and thus a ~3-folder greater number of transfected cells for F98 over microglial 
cells was not readily assumed. It is most likely that passive mechanisms have been involved. A 
relatively larger number of F98 cells in the tumor tissue as well as high endocytic activities often 
observed with tumor cells (62-64) may render them a better “particle sink” compared to other 
brain-resident cells, such as microglial cells. In addition, mitotic activities of brain-resident cells 
are very low, whereas glioma cells are highly mitotic (39), thereby enhancing the probability of 
plasmid payloads entering into the nucleus to be transcribed. We note that while the described 
are reasonable scenarios, further mechanistic underpinning should be followed to elucidate a 
full picture.
 







































Figure 2.13: Transgene expression mediated by BPNH carrying ZsGreen-expressing plasmids in 
F98-mKate orthotopic rat tumor tissues.  Representative confocal images at 40X magnification showing 
(A) F98 tumor cells (red; mKate), (B) microglia (cyan; Iba1), (C) transgene expression (green; ZsGreen) 
and (D) overlay. Scale bar = 50 µm. (E) Quantification of percentage of F98 tumor and microglia cells with 
the transgene expression. ***denotes a statistically significant difference (p < 0.001).  
  F98     Microglia  
A         B        
C         D       





Here, we introduce a novel polymer-based gene vector capable of efficiently penetrating both 
healthy brain parenchyma and brain tumor tissue. Specifically, a lead formulation, BPNH, 
exhibited the greatest ability to provide widespread and high-level transgene expression in 3D 
tumor spheroids and orthotopically-established brain tumors compared to formulations with 
inferior surface PEG coatings, with an excellent in vitro-to-in vivo correlation. We note that while 
the transgene expression occurred preferentially in gliomas cells within orthotopically-
established tumor tissue, a significant expression was observed in microglial cells as well. Thus, 
an additional strategy is likely needed if highly selective cancer cell transfection is required, 
while retaining the ability to cover widely scattered tumor areas within the brain. To this end, our 
current effort focuses on achieving widespread but cancer-selective therapeutic transgene 
expression via a marriage of BPNH and promoters designed to drive transgene expression 
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Widespread gene transfer to brain tumors via biodegradable polymer-based DNA nanoparticles 
Abstract 
Biodegradable DNA nanoparticles offer a safe non-viral gene delivery platform devoid of 
adverse effects associated with synthetic nonbiodegradable systems. State-of-the-art 
biodegradable polymer, poly(β-amino ester) (PBAE), forms colloidally stable sub-100 nm DNA-
brain penetrating nanoparticles (BPN) that sufficiently penetrate and transfect healthy and brain-
tumor tissue. We have developed a series of PBAE polymer variants possessing different end-
capping groups (Cx; x = 1-8) that have successfully shown DNA complexation and colloidal 
stability in artificial cerebrospinal fluid. Furthermore, nanoparticle characterization in three-
dimensional multicellular in vitro tumor model, and in vivo, established a new BPN formulation, 
named BPN-C8, as the leading nanoparticle formulation for better widespread, yet safe, 
transgene expression in mice brain tissue after local administration. Moreover, for the first time 
we showed BPN-C8 achieving widespread tumor gene transfer in three highly aggressive 
orthotopic brain tumor models: GL261 (mouse glioblastoma), BT37 and CHLA-06 (AT/RT cell 
lines derived from pediatric human xenografts). Lastly, we successfully developed a method for 
cryo-protection of this BPN without compromising their penetrating properties nor their 
transgene expression efficiency. This provides a promising delivery platform for localized gene 









As previously discussed, achieving widespread gene transfer in the brain parenchyma is 
crucial in order to experience complete cure or survival benefits when treating brain tumors via 
gene therapy platforms. Given this significant challenge, our group has focused on developing 
polymer-based DNA-loaded brain penetrating nanoparticles (BPN) possessing favorable 
physicochemical properties, including colloidal stability in physiological environments and in 
vivo. Importantly, we have previously demonstrated that synthetic BPNs, made with lead 
polymers tested in clinical trials, albeit not for brain, including polyethyleneimine (PEI) (1-6) and 
poly-L-lysine (PLL) (7), when possessing small particle diameters (<100 nm) and non-adhesive 
surface coatings with dense polyethylene glycol (PEG), can be locally administered via 
convection-enhanced delivery (CED) to provide widespread gene transfer in healthy brain 
tissues (8, 9). Furthermore, we recently reported that PEI-BPN with heavier PEG coatings, and 
the state-of-the-art biodegradable polymer-based poly(β-amino ester) (PBAE) BPN can also 
achieve widespread gene transfer in orthotopic brain tumors after CED (PEI-BPN studies shown 
in Chapter 2) (10). Encouragingly, PBAE BPN demonstrated significant anti-tumor efficacy in 
F98 rat glioblastoma and 9L rat gliosarcoma tumor models when carrying plasmids encoding for 
thymidine kinase and p53 gene, respectively, whereas PBAE unPEGylated nanoparticles (UPN) 
were unable to do so (11).  
Anderson D. G., Lynn D. M., and Langer R. described the first synthesis and high-
throughput screening from a large library of PBAE polymers variants, composed of ~2350 
candidates, and confirmed their ability to achieve gene transfer in mammalian cell culture (12). 
Since then, a series of other PBAE generations have been reported in the literature as strong 
candidates for in vitro gene transfer in various cell types with potential use for in vivo 
applications (13-19). Here, we identified a few (up to eight) candidates that possess different 
terminal ends previously shown to provide excellent in vitro efficiency and sought to engineer 
and test BPN formulated based on these variants for widespread transgene expression in brain.  
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While two-dimensional (2D) monolayer cells, cultured on flat and rigid surfaces, have been 
widely used for screening DNA-loaded nanoparticles and other transfection reagents, i.e. viral 
vectors and lipofectamine, its limitations have been increasingly recognized (20). Although the 
time-honored 2D cell culture has proven to be a valuable method for cell-based studies, it has 
been reported the 2D in vitro and in vivo do not correlate (20). In Chapter 2, we found that it is 
reverse-correlated. On the other hand, it has been shown that three-dimensional (3D) 
multicellular spheroids, represent more accurately the actual microenvironment where cells 
reside in tissues (20), which served as a reliable model to predict in vivo performances of DNA-
loaded nanoparticles, confirmed in our previous PEI-BPN studies from Chapter 2. Here we thus 
formulated and thoroughly characterized BPN based on PBAE variants and test in vitro with 3D 
model and in vivo with healthy and tumor-bearing mice brain tissue. Lastly, we then formulated 
a “ready-to-use” lyophilized version of the lead BPN candidate for long-term storage and 
pertinent clinical applications.  
2. Materials and Methods 
2.1 Polymer synthesis 
For the PBAE backbone polymer, monomers 1,4-butanediol diacrylate and 4-amino-1-
butanol were purchased from Alfa Aesar (Ward Hill, MA). For the end-capping groups, C1 (1,3-
diaminopropane) and C2 (2,2-dimethyl-1,3-propanediamine) were purchased from Sigma-
Aldrich (St. Louis, MO); C3 (N-(3-aminopropyl)pyrrolidine) was purchased from Acros Organics 
(New Jersey); C4 (1-(3-aminopropyl)-4-methylpiperazine) was purchased from Alfa Aesar; C5 
(2-(3-aminopropylamino) ethanol) was purchased from Oakwood Chemical (West Columbia, 
SC); C6 (N,N-bis(2-hydroxyethyl)ethylenediamine) was purchased from Alfa Aesar; C7 (N-(3-
aminopropyl)diethanolamine) and C8 (1,11-diamino-3,6,9-trioxaundecane) were purchased from 
Tokyo Chemical Industry (Cambridge, MA). For the PEGylation reaction, methoxy-PEG-
succinimidyl succinate from JenKem Technology (Plano, TX). Solvents were purchased as 
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follows: ethyl ether anhydrous from Fischer Scientific (Pittsburgh, PA); dimethyl sulfoxide 
anhydrous (DMSO) and tetrahydrofuran (THF) from Sigma-Aldrich.  
Following an in-depth literature search (13, 14, 16, 19, 21-24), we established a series of 
leading PBAE polymers previously shown to provide efficient in vitro gene transfer (Figure 3.1). 
PBAE polymers were synthesized by a two-step Michael addition reaction, as previously 
reported (24, 25). First, 1,4-butanediol diacrylate and 4-amino-1-butanol were reacted at a 1.1:1 
molar ratio at 90 °C for 24 hours to synthesize high–molecular-weight (MW) uncapped PBAE 
polymer (6.0–6.5 kDa). Polymers were then precipitated in cold ether three times to remove any 
unreacted species, dried under vacuum, and lyophilized. The molecular mass of 6.0–6.5 kDa 
was estimated using NMR, assuming two end acrylate groups per polymer and characterized by 
gel permeation chromatography (GPC) (see Mastorakos et al. 10.1073/pnas.1502281112, 
PNAS supplementary materials for NMR and GPC details) (24). For capping of the end acrylate 
groups, PBAE backbone polymer was dissolved in THF at 100 mg/mL and 30 molar equivalents 
of one of C1–C8 capping groups was added (to ensure end capping rather than further 
propagation). The reactions occurred while stirring at room temperature for 4–5 hours. The end-
capped PBAE polymers were retrieved by precipitation in cold ether to remove unreacted 
groups, dried under vacuum, and lyophilized. Purity and complete end capping were confirmed 
by the absence of the acrylate proton peaks in the NMR spectrum (data not shown) (24). 
For the synthesis of PEGylated PBAE polymer (PEG-PBAE), a three-step reaction scheme 
was used. First, a PBAE polymer possessing lower MW was synthesized by reacting 1,4-
butanediol diacrylates and 4-amino-1-butanol at a 1.2:1 molar ratio. Based on NMR analysis, 
the molecular mass was estimated to be 3.8–4.2 kDa, assuming two end acrylate groups per 
polymer. The low-MW PBAE polymer was then capped with C1 as described earlier, and the 
end capping was confirmed by NMR. Subsequently, methoxy-PEG succinimidyl succinates 
were reacted with the two terminal primary amine groups at both ends of the C1-capped PBAE 
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polymer chain. To do this, we transferred the resulting PBAE-C1 polymer and 2.05 molar 
equivalents of 5 kDa methoxy-PEG-succinimidyl succinate to a glass vial, vacuumed, and 
purged with nitrogen. The mixture of reactants was dissolved in THF and reacted while stirring 
at room temperature overnight. The final PEG-PBAE polymer product was precipitated and 
washed with cold ether three times, dried under vacuum, and lyophilized. PEG conjugation was 
confirmed with NMR. Of note, the lower-MW PBAE polymer was used for the synthesis of PEG-
PBAE (at a PEG-to-PBAE molar ratio of 2:1) to increase the PEG-to-PBAE weight-to-weight 
(wt/wt) ratio of the individual PEG-PBAE polymers and, thus, achieve a higher PEG content 
when particles are formulated at a fixed amount of PBAE polymer. All polymers were dissolved 
in DMSO at 100 mg/mL and stored at −20 °C for further use. Previous publications from our 
group used PBAE-C5 as a core polymer for the formulation of BPN (10, 11, 24), however, this is 
the first time we test all eight variants in the brain for gene transfer in malignant tumors followed 
by intracranial administration.  
 
 





B              
Figure 3.1: Poly(β-amino esters) (PBAE) polymer variants. (A) Chemical structure of the 
polymer backbone. (B) Chemical structure of the different end-capping groups used to 

























2.2 Nanoparticle formulation 
The luciferase-expressing plasmids driven by the short-acting cytomegalovirus (CMV) 
promoter (i.e. pd1GL3-RL) was a kind gift from Professor Alexander M. Klibanov (M.I.T). The 
ZsGreen-expressing plasmid driven by the CMV promoter was purchased from Clontech 
Laboratories Inc. (Mountainview, CA). Plasmids were propagated and purified, as previously 
described (11, 26). Briefly, plasmids were transformed into E. coli DH5α competent bacterial 
cells using a heat shock method, and following the bacterial expansion in LB media, plasmids 
were purified using EndoFree Plasmid Giga Kit (QIAGEN, Valencia, CA), as per manufacturer's 
protocol. 
PBAE UPN were formulated and characterized as previously reported (10, 11, 21). BPN 
were formulated using a protocol we have recently established (11). Briefly, 5 volumes of 
plasmid DNA (0.1 mg/ml) were added drop-wise to 1 volume of polymer solution, consisting of a 
mixture of PBAE and PEG-PBAE at a w/w ratio of 2:3 based on PBAE mass and at a PBAE to 
plasmid DNA ratio of 60:1 w/w. Using a 0.1 M hydrochloric acid solution, both the DNA and the 
polymer solutions were adjusted to pH 6.0. Following formulation, nanoparticles were washed 
with 3 volumes of ultrapure water, and concentrated to 1 mg/ml of plasmid DNA using Amicon® 
Ultra Centrifugal Filters (100,000 MWCO, Millipore Corp., Billerica, MA) as measured using the 
Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies, Grand Island, NY). The 
hydrodynamic diameters as well as polydispersity index (PDI) and ζ-potentials of UPN and 
BPN-Cx were measured by dynamic light scattering (DLS; in ultrapure water) and laser Doppler 
anemometry (in 10 mM NaCl solution at pH 7.0), respectively, using a Nanosizer ZS90 (Malvern 
Instruments, Southborough, MA). The size and morphology of nanoparticles were also 
confirmed by transmission electron microscopy (TEM) (Hitachi H7600, Japan). The DNA 
complexation was confirmed by conventional agarose gel-based electrophoretic analysis. 
Colloidal stability was assessed by monitoring the change in hydrodynamic diameters and PDI 
in artificial cerebrospinal fluid (aCSF) (Harvard Apparatus, Holliston, MA) at 37 °C.  
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2.3 Cell culture 
Highly aggressive mice GL261 glioblastoma cells were provided by Dr. Kannan 
Rangaramanujam. Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium 
purchased from ThermoFischer Scientific (Waltham, MA) supplemented with 1% L-Glutamine, 
10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin from Invitrogen 
Corp. (Carlsbad, CA). Upon reaching the confluent state, the monolayers were treated with 
trypsin and the dispersed cells were transferred into new culture flasks. The spheroid media for 
GL261 cells was prepared by dissolving autoclaved methylcellulose from Sigma-Aldrich at 2.4% 
(w/v) in preheated (60 °C) serum-free RPMI followed by dilution with an equivolume of RPMI 
supplemented with 10% FBS and an overnight stirring at 4 °C. The solution was then 
centrifuged at 5,000 x g for 2 hours at 4 °C to precipitate undissolved methylcellulose and the 
supernatant stored at 4 °C until use. The in vitro studies in three-dimensional (3D) multicellular 
spheroids and in vivo studies were conducted when GL261 cells reached 70% - 80% confluency 
in the flask.  
Highly aggressive pediatric BT37 and CHLA-06 AT/RT cells, derived from human xenografts, 
were provided by Dr. Eric H. Raabe (27). BT37 cells were cultured in RPMI-1640 medium 
containing 1% penicillin/streptomycin, and 20% FBS. CHLA-06 cells were initially cultured as 
neurospheres in modified Neurobasal medium consisting of 1:1 DMEM:F12 containing 15 mM 
HEPES purchased from StemCell Technologies (Cambridge, MA), 110 mg/L sodium pyruvate 
from ThermoFischer Scientific, 1.2 g/L sodium bicarbonate, B27 supplement from Gibco (Grand 
Island, NY), 20 ng/mL epidermal growth factor from Peprotech, Inc. (Rocky Hill, NJ), 20 ng/mL 
basic fibroblast growth factor (Peprotech), and 25 µg/ml gentamicin (Gibco). Gentamicin was 
removed after the first 2 weeks of culture. For BT37, upon reaching the confluent state, the 
monolayers were treated with trypsin and the dispersed cells were transferred into new culture 
flasks. For CHLA-06 suspension cells, the passaging was at ratio of 1:2–3 with 25% (v/v) 
conditioned medium in the new flask every 4 to 5 days. The cultures were incubated at 37°C in 
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a humidified atmosphere of 5% CO2. Both AT/RT cell lines used in this manuscript were 
previously authenticated to be human and did not match the short tandem repeat profile of any 
other cell line in the established databases (ATCC, DSMZ, and JCRB) (27).  
2.3.1 Cellular uptake 
Cells were seeded onto 6-well plates at an initial density of 200,000 cells/well and grown 
overnight at 37 °C. Cells were treated with the various BPN carrying Cy5-labeled plasmids (5 μg 
DNA/well) and after 5 hours of incubation, the media was removed. Cells were then thoroughly 
washed with 1X phosphate buffered saline (PBS) and trypsinized. Flow cytometry was 
conducted to quantify the cellular uptake of DNA-NP using a Sony Cell Sorter SH800 (Sony, 
San Jose, CA), followed by data analyzed with a FlowJo software (FlowJo LLC, Ashland, OR). 
2.3.2 Luciferase assay 
Cells were seeded at an initial density of 5,000 cells/well onto 96-well plates and grown 
overnight at 37 °C. Cells were then treated with the various BPN carrying luciferase-expressing 
plasmids (i.e. pd1GL3-RL) at a plasmid concentration of 0.5 μg/well, and the culture media was 
replaced with fresh media 5 hours after the incubation. After 48 hours of additional incubation, 
media was removed and 100 µl of 1X Reporter Lysis Buffer purchased from Promega (Madison, 
WI) was added. Subsequently, cells were subjected to three freeze-and-thaw cycles to achieve 
complete lysis followed by the collection of supernatants by centrifugation. Luciferase activity 
was measured in relative light units (RLU) using a standard Luciferase Assay Kit (Promega) and 
a 20/20n luminometer (Turner Biosystems, Sunnyvale, CA). The RLU values were normalized 
to the total protein content measured by a Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo 
scientific). 
2.3.3 Transgene expression in 3D multicellular spheroids 
3D multicellular spheroids were established by the hanging-drop method as previously 
described in Chapter 2. Briefly, for each spheroid, 5,000 GL261 cells were suspended in 20 µL 
of spheroid media on the lid of a petri-dish. Spheroids were then grown upside down by 
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covering a PBS-filled/moisturized petri-dish with the cell-seeded lid for 2 days. Then, spheroids 
were transferred onto a sterile U-bottom 96-well plate (CELLSTAR®) (Sigma-Aldrich, St. Louis, 
MO) along with RPMI 1640 Medium (ThermoFischer Scientific, Waltham, MA) and incubated at 
37⁰C for 48 hours prior treatment. Subsequently, GL261 spheroids were treated with the various 
BPN formulations carrying ZsGreen-expressing plasmids (1 μg plasmids/spheroid). After 48 
hours of additional incubation, the spheroids were transferred on to poly-d-lysine coated 35 mm 
glass bottom dishes (MatTek Corp., Ashland, MA). Fluorescence images were then captured 
using an LSM 710 confocal microscope (Carl Zeiss; Hertfordshire, UK) under 10X magnification 
and analyzed for spheroid area-normalized mean fluorescence intensity using an ImageJ 
software (NIH, Bethesda, MD). 
2.4 Animal studies 
Female C57BL/6 mice, 6–8-week-old, were used for the assessment of in vivo gene transfer 
of UPN and the various BPN formulations in healthy and GL261 tumor tissue. Female NSG 
mice, 6-8-week-old, were used for assessment of in vivo gene transfer of BPN-C8 in BT37 and 
CHLA-06 tumor tissue.  All animals were treated in accordance with the policies and guidelines 
of the Johns Hopkins University Animal Care and Use Committee.  
2.4.1 Orthotopic tumor inoculations 
Surgical procedures were performed using standard sterile surgical techniques. 
Intracranial xenografts were produced in anesthetized animals using a mixture of 75 mg/kg 
ketamine and 7.5 mg/kg xylazine, as previously described (28-30). For GL261 tumors, a midline 
scalp incision was made to expose the coronal and sagittal sutures and a burr whole was drilled 
2 mm lateral to the sagittal suture and 0.5 mm anterior to the bregma. Then 100,000 GL261 
viable cells were administered in 2 µL of RPMI 1640 Medium over 2 minutes at a depth of 3.5 
mm using a Neuros syringe (Hamilton, Reno, NV) mounted on an ultra-precise small-animal 
stereotactic frame (Stoelting Co., Wood Dale, IL). For BT37 and CHLA-06 human xenografts, 
injection guide holes were produced by an 18-gauge beveled needle from, where 100,000 
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viable cells were administered in 5 µl of respective growth medium into the right striatum 2 mm 
lateral to the sagittal suture and 3 mm anterior to the bregma at a depth of 3 mm using a Neuros 
syringe mounted on an ultra-precise small-animal stereotactic frame. Following the tumor cell 
inoculation, the skin was sealed with a 9 mm Autoclip Applier using stainless steel wound clips 
(Braintree Scientific Inc., Braintree, MA). 
2.4.2 Intracranial administration – CED 
Various nanoparticles carrying ZsGreen- or luciferase-expressing plasmids were 
intracranially administered via CED, as previously described (9, 10). Briefly, a Neuros syringe 
connected to a 33-gauge needle was filled with 2 μL of nanoparticle solution at a plasmid 
concentration of 0.5 mg/mL and lowered to a depth of 3.0 or 2.5 mm, for healthy or orthotopic 
tumor-bearing mice brain, targeting the striatum or the tumor core, respectively. Note that for 
safety analysis, sterile medical-grade normal saline was administered as a control. The solution 
was then infused at a rate of 0.22 μL/min as controlled by a Chemyx Nanojet Injector Module 
(Chemyx, Stafford, TX). Following the administration, the skin was sealed using biodegradable 
sutures (Polysorb™ Braided Absorbable Sutures 5–0) and bacitracin was applied. 
2.4.3 Distribution of transgene expression 
To assess the distribution of transgene expression, brain tissues of mice that received 
UPN or various BPN carrying ZsGreen-expressing plasmids were harvested 48 hours after the 
administration and subsequently fixed with 4% formaldehyde. Tissues were then sectioned 
using a Leica CM 1905 cryostat into 50 μm coronal slices at ± 3 mm of the infusion plane in 
striatum or until the tumor tissue was no longer visible. Slices of orthotopic tumor tissues were 
stained with DAPI (Molecular Probes, Eugene, OR) to visualize tumor cell nuclei. All 
fluorescence images were taken using an LSM 710 confocal microscope under 5X 
magnification. We carefully optimized the settings to avoid background fluorescence based on 
the microscopy of untreated control rat brains. The volume of transgene expression was 
quantified using a custom-made MATLAB script that subtracted background fluorescence by 
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Otsu’s method of thresholding (31, 32). The area of transgene expression in each slice was 
integrated to calculate the total volume of transgene expression. To reconstruct 3D-rendered 
images of volumetric transgene expression, we stacked and aligned the acquired images using 
Metamorph ® Microscopy Automation & Image Analysis Software (Molecular Devices, CA). 
Finally, we used an Imaris Software (Bitplane, CT) to create 3D isosurfaces of the reconstructed 
images. 
To quantify the overall level of transgene expression, we treated mice using the identical 
dosing method applied to the distribution study but with UPN or various BPN carrying luciferase-
expressing plasmids (i.e. pd1GL3-RL). Brains were harvested 72 hours after the administration 
and subjected to homogenate-based luciferase assay using a standard Luciferase Assay Kit 
and a 20/20n luminometer. The RLU values were normalized to the total protein content 
measured by BCA protein assay.  
2.4.4 Histological analysis and safety profile 
Animals were sacrificed 3 days following administration and the harvested brains were fixed 
in 4% formaldehyde, processed, sectioned and stained with hematoxylin and eosin (H&E) by 
the Johns Hopkins Reference Histology Laboratory. The point of infusion was identified by the 
tissue cavity imparted by the needle and the region immediately adjacent was imaged and 
evaluated. Blind histopathological analysis was performed by a board-certified neuropathologist 
and tissues were scored from 0–3 for indications of inflammation and hemorrhage (0: no 
inflammation/hemorrhage, 1: mild, 2: moderate, 3: severe). 
2.5 Lyophilization of BPN 
For lyophilized nanoparticle formation and evaluation, BPN were initially formed as 
described above. Subsequently, sucrose (OPS Diagnostics, Lebanon, NJ) was added as a 
cryoprotectant to a final concentration of 30 mg/mL, diluting BPN 2-fold. BPN were frozen in dry-
ice and lyophilized overnight. Lyophilized BPN were stored at -20 °C until use and were then 
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reconstituted in sterile ultrapure water and used at the same concentration as freshly prepared 
BPN. 
2.6 Statistical Analysis 
Statistical analysis between two groups was conducted using a two-tailed Student's t-test 
assuming unequal variances. If multiple comparisons were involved, one-way analysis of 
variance (ANOVA), followed by Sidak's multiple comparisons test, was employed, using 
GraphPad Software (GraphPad Software Inc., La Jolla, CA). Differences were determined to be 
statistically significant at p < 0.05. Values are presented as mean ± standard error of the mean 
(SEM).  
3. Results 
3.1 Physicochemical characterization of UPN and BPN 
We complexed DNA into nanoparticles with one of the PBAE polymer variants possessing 
different end-capping groups (Cx; x = 1-8; Figure 3.1) consisting of a mixture of PBAE and 
PEG-PBAE at a w/w ratio of 2:3 based on PBAE mass and at a PBAE to plasmid DNA ratio of 
60:1 w/w to form BPN. Hydrodynamic diameter and PDI were measured by DLS in ultrapure 
water. The ζ-potential was measured by laser Doppler anemometry in 10mM NaCl at pH 7.0. 
At least 3 independent experiments were performed for this analysis. Table 3.1 shows that all 
BPN-Cx, possessed a hydrodynamic diameter of ~60 nm, a low PDI ~0.1, and near neutral 
surface charge as indicated by ζ-potential ~3-4 mV when freshly made in ultrapure water; 
whereas BPN-C6 possessed a higher PDI of 0.2 and a highly cationic surface charge of 14.8 ± 
1.2 mV. For control purposes, UPN were formulated and characterized as previously reported 
(10, 11, 21). Figure 3.2 shows that UPN possessed a hydrodynamic diameter of 130 ± 11 nm 
and highly cationic surface charge of 26 ± 6.5 mV when freshly made in ultrapure water. 
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The particle morphology was confirmed by TEM to be ~60 nm spheres regardless of end-
capping groups (only BPN-C6 and BPN-C8 are shown in Figure 3.3A), consistent with the 
measured hydrodynamic diameters (Table 3.1). We then verified robust DNA compaction in all 
eight BPN compared to free plasmid via a conventional agarose-gel migration assay (Figure 










 SEM at 4 hours 
in aCSF (nm)d
PDI 
at 4 hours 
in aCSFd
C1 60 ± 5 0.09 3.6 ± 2.6 79 ± 10 0.28
C2 60 ± 2 0.09 2.8 ± 2.8 64 ± 3 0.40
C3 67 ± 1 0.07 4.3 ± 2.3 74 ± 21 0.30
C4 58 ± 5 0.13 6.5 ± 0.5 62 ± 1 0.28
C5 62 ± 2 0.09 4.2 ± 0.7 80 ± 5 0.20
C6 65 ± 9 0.20 14.8 ± 1.2 271 ± 14 0.41
C7 63 ± 2 0.07 1.7 ± 0.9 67 ± 8 0.38
C8 60 ± 1 0.07 4.5 ± 0.8 73 ± 2 0.04
Table 3.1: Physicochemical properties of different BPN formulations. 
a 
Each BPN was formulated with one of the core PBAE polymer variants possessing 
different end-capping groups (Cx; x = 1-8; Figure 3.1) 
b 
Hydrodynamic diameter and polydispersity index (PDI) were measured by 
dynamic light scattering (DLS) in ultrapure water. Mean ± SEM (n ≥ 3).  
c 
ζ-potential was measured by laser Doppler anemometry in 10mM NaCl at pH 7.0. 
Mean ± SEM (n ≥ 3).  
d 
Hydrodynamic diameter and PDI were measured by DLS following a 4-hour 
incubation in aCSF at 37⁰C. 








































Figure 3.2: Physicochemical characterization of UPN. (A) Transmission 
electron micrograph of fresh UPN formulated in ultrapure water. Scale bar = 
800 nm. (B) Hydrodynamic diameter was measured by dynamic light 
scattering (DLS) in ultrapure water (n ≥ 3). (C) 
 
ζ-potential was measured by 
laser Doppler anemometry in 10 mM NaCl at pH 7.0 (n ≥ 3).  
A                     B                        C  
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incubation in aCSF at 37⁰C to predict potential alteration of particle properties in the 
physiological brain environment. We found most BPN formulations slightly increased their 
hydrodynamic diameters in aCSF to ~70-80 nm and their PDI to ~0.3 (Table 3.1). Notably, BPN-
C8, although with slight increase, retained the diameter for up to 5 hours at 73 ± 2 nm and 
maintained a very low PDI of 0.04, whereas BPN-C6 incremented to a size of 271 ± 14 nm and 
showed a high PDI of 0.41 (Figure 3.3C). This suggests that BPN-C6 would be unlikely to 
efficiently penetrate brain tissues due to large particle size as well as positively charged particle 
surfaces.   
               
3.2 Transgene expression in healthy mice brains  
UPN and various BPN carrying ZsGreen-expressing plasmids were administered into the 
mice striatum via CED that has been clinically applied to enhance the therapeutic distribution 
within brain by creating a continuous pressure-driven bulk flow (31, 33). Transgene expression 
was then assessed 48 hours after the treatment. The 3D reconstruction of confocal images of 
serial coronal sections of rat brains revealed enhanced volumes of transgene expression when 
mice were treated with BPN-C5 and BPN-C8 (Figure 3.4A). In agreement with our previous 
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Figure 3.3: Physicochemical characterization of BPN formulations. (A) 
Transmission electron micrographs of BPN-C6 (left) and BPN-C8 (right). Scale bar 
= 400 nm. (B) Gel electrophoretic analysis demonstrating complexation of plasmids 
by different BPN formulations (FP = free plasmid; BPN-Cx; x = 1 - 8). (C) Colloidal 
stability of BPN-C6 and BPN-C8 in aCSF at 37°C over 5 hours, measured by DLS. 
The difference is statistically significant as indicated (***p < 0.001). 
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administration (image not shown) despite the pressure gradient provided by CED, giving a 
volume of transgene expression of 0.6 ± 0.2 mm3. Most BPN variants, except for BPN-C6 and 
BPN-C7, exhibited significantly greater volumetric distribution of transgene expression 
compared to UPN (Figure 3.4B). Notably, BPN-C8 and BPN-C5 showed the two highest values 
for distribution of transgene expression, 7.2 ± 0.4 mm3 and 5.9 ± 1.2 mm3, respectively. 
Importantly, BPN-C8 roughly doubled the transfected volume on average in the mice striatum 
compared to BPN-C6 (3.1 ± 1.0 mm3; p < 0.05; Figure 3.4B).  
In parallel, we quantitatively determined the overall levels of transgene expression 
mediated by CED of UPN and the various BPN carrying luciferase-expressing plasmids, using a 
homogenate-based luciferase assay. BPN-C8 exhibited the highest levels of transgene 
expression (134,813 ± 23,262 RLU/mg of protein), with ~600-fold greater luciferase activity in 
comparison to UPN (219 ± 26 RLU/mg of protein) (Figure 3.4C). Furthermore, BPN-C8 
exhibited statistically significant improvements (p < 0.05) with ~1.8-fold greater luciferase 
activity in comparison to BPN-C5, which was the next variant with the highest level of transgene 
expression (74,003 ± 13,969 RLU/mg of protein; ~330-fold greater than UPN). The findings here 
suggest that the unique ability of BPN-C8 to further increase the volumetric distribution of 




3.3 Histopathological analysis and safety profile 
To demonstrate the safety of PBAE-based nanoparticles followed by intracranial 
administration by CED, we compared the toxicity of UPN, BPN-C6, and BPN-C8 to medical-
grade normal saline by histology safety profile in the mice striatum. Followed 3 days from the 
nanoparticle administration, the average toxicity scores of the brain tissues for UPN and both 
BPN were comparable to those of normal saline-treated controls (Figure 3.5), with an average 
score of ~1.5-2 for hemorrhage and ~0.5-1.5 for inflammation, suggesting that they were well-
tolerated at the dose administered (0.5 mg/mL, 2 μL). Notably, the inflammation score increased 

























































































































Figure 3.4: Transgene expression mediated by CED of different BPN formulations carrying ZsGreen- or 
luciferase-expressing plasmids in healthy mouse brain tissues. (A) Representative isosurface 3D images 
depicting volumetric distribution of ZsGreen reporter transgene expression (green) in healthy mice brains 48 
hours after the treatment carrying, obtained by stacking multiple sequential confocal images. Scale bar = 1 
mm. (B) Volume of ZsGreen transgene expression (n ≥ 6 mice). UPN denotes an un-PEGylated nanoparticle 
control. (C) Overall level of luciferase transgene expression (n ≥ 6 mice). Differences are statistically significant 
compared to BPN-C8 as indicated (*p < 0.05; **p < 0.01; ***p < 0.001). All BPN formulations exhibit 
statistically significant differences compared to UPN as indicated (#p < 0.05).  
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regardless of the gene vector type, inflammatory and hemorrhagic changes were confined 
around the injection site and did not propagate throughout the brain tissue. 
        
3.4 Transgene expression in GL261 tumor cells  
We have previously confirmed that in vitro screening of gene vectors in two-dimensional 
(2D) culture is not accurate to predict in vivo gene transfer in the brain (Chapter 2). Despite this 
limitation, we assessed in vitro cellular uptake and transfection efficiency of the various BPN 
carrying Cy5-labeled and unlabeled luciferase-expressing plasmids, respectively, using a 
GL261-based 2D cell culture. As expected from our previous studies, there was no clear 
difference between the cellular uptake/mean intensity and the transfection efficiency of the eight 
BPN variants (Figure 3.6). To this end, we constructed a 3D tumor-spheroid model with GL261 
cells and assessed the transgene expression of the various BPN carrying ZsGreen-expressing 
plasmids. As shown by representative confocal images (Figure 3.7A), four BPN (C1, C3, C5, 
and C8) exhibited greater levels of transgene expression compared to the other four variants 
(C2, C4, C6, and C7). Among the top four variants, BPN-C8 > BPN-C5 > BPN-C3 > BPN-C1. 
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Figure 3.5: Histopathological analysis and safety profile of different BPN 
formulations in comparison to UPN following intracranial administration by CED. 
(A) Representative images showing H&E staining at the infusion site in healthy mouse 
brain tissue 3 days after nanoparticle administration (40X magnitude). Normal saline was 
infused as a control. Scale bar = 100 µm. (B) Inflammation and hemorrhage in healthy 
brain tissues were scored by a board-certified neuropathologist using a custom scale (0: 
no inflammation/hemorrhage; 1: mild; 2: moderate; 3: severe).  
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Quantitatively, BPN-C8 showed significantly greater level of transgene expression (11.6 ± 1.7 
a.u.), as measured by mean fluorescence intensity, compared to BPN-C1 (7.2 ± 0.9 a.u.; p < 
0.05), BPN-C2 (3.7 ± 0.3 a.u.; p < 0.001), BPN-C4 (6.3 ± 0.6 a.u.; p < 0.01), BPN-C6 (3.3 ± 1.6 
a.u.; p < 0.001), BPN-C7 (4.8 ± 0.9 a.u.; p < 0.001) (Figure 3.7B). This is also in agreement with 
the volume of transgene expression seen in vivo, which suggests the unique ability of BPN-C8 
to further increase the volumetric distribution of transgene expression over our previously 
reported BPN-C5, and the poor gene transfer of BPN-C6.  
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Figure 3.6: Cell uptake and transfection of BPN candidates in 2D cell cultures. (A) Flow cytometric 
analysis of percentage cell uptake and median fluorescence intensity (i.e. degree of cell uptake per cell) 5 
hours after treatment with BPN candidates carrying ZsGreen-expressing plasmids or a respective carrier-free 
plasmid (FP) control. (B) In vitro luciferase transgene expression 48 hours after treatment with BPN 
candidates carrying luciferase-expressing plasmids or a respective FP control. The differences between all 
BPN candidates and respective FP controls are statistically significant (#p < 0.05; **p < 0.01; ***p < 0.001). 
A                                                B  
106 
 
               
3.5 Transgene expression in orthotopic brain tumors 
The Gl261 tumor is one of the few available murine glioma models. Originally this tumor was 
induced originally by intracranial injection of 3‐methylcholantrene into C57BL/6 mice and 
propagated in vivo by transplanting small tumor pieces on its syngeneic host (34). This tumor 
model was used in many immune therapeutic and gene therapeutic investigations, and it is 
included among the aggressively growing tumors, compared to 9L and F98 (previous work). In 
contrast, the C6 rat glioma and the 4C8 mouse glioma models are much less aggressive (35). 
Furthermore, Gl261 cells and the ‘original’ brain tumor contain several molecular biological 











































Figure 3.7: Transgene expression by BPN formulations in GL261-based 3D 
spheroids. (A) Representative reporter transgene expression (green) by BPN 
carrying ZsGreen-expressing plasmids 48 hours after the treatment. Scale bar = 
250 µm. (B) Quantification of ZsGreen transgene expression within the 
spheroids. Differences are statistically significant as indicated (*p < 0.05; **p < 
0.01; ***p < 0.001).  
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alterations characteristic of human gliomas, such as p53 and K-RAS mutations, and it is only 
moderately immunogenic (36).  
We next evaluated in vivo gene transfer efficacy of BPN-C6 and BPN-C8 carrying ZsGreen-
expressing plasmids in the orthotopic model GL261, following CED. The CED experiment was 
conducted 12 days after the inoculation. BPN-C6 was used as a negative control. As shown by 
representative 3D-reconstructed images, BPN-C8 exhibited the greatest volumetric distribution 
of transgene expression (7.4 ± 1.2 mm 3), which is ~1.8 greater than BPN-C6 (p < 0.05) (Figure 
3.8). We then quantified the volumetric fractions of the GL261 tumor with reporter transgene 
expression mediated by the nanoparticles. The percentages of total tumor volumes exhibited 
positive reporter transgene expression were ~85% and ~53% for BPN-C8 and BPN-C6, 
respectively (p <0.05).  
 
Atypical teratoid/rhabdoid tumors AT/RTs are highly aggressive and deadly pediatric brain 
tumors with a very poor prognosis (37). Therapeutic failure in aggressive brain tumors such as 
AT/RTs is due to the lack of potency of existing agents, intratumoral and intertumoral 
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Figure 3.8: Transgene expression mediated by CED of BPN formulations carrying 
ZsGreen-expressing plasmids in GL261-based orthotopic tumor tissues. (A) Representative 
isosurface 3D images depicting volumetric distribution of reporter transgene expression (green) in 
orthotopic brain tumors (outlined by blue-dashed lines) 48 hours after the treatment, obtained by 
stacking multiple sequential confocal images. Scale bar = 1 mm. (B) Volume of transgene 
expression (n ≥ 3 mice) and percentage of tumor volume covered by transgene expression (n ≥ 3 
mice). Differences are statistically significant as indicated (*p < 0.01).  
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heterogeneity, and activation of anti-apoptotic and metabolic programs that allow tumor cells to 
survive treatment (38). AT/RTs share many characteristics with stem cells, including an ability to 
differentiate into cells with neuronal and “rhabdoid” features, as well as resistance to 
transfection reagents, chemotherapy and radiation (27). Identification and validation of novel 
gene targets and delivery strategies are essential to develop better therapies and improve the 
dismal prognosis of these lethal pediatric tumors.  
Since BPN-C8 demonstrated better widespread transgene expression in healthy and brain 
tumor tissue compared to the other candidates, we continued our studies for in vivo gene 
transfer of BPN-C8 in human xenografts for AT/RTs, BT37 and CHLA-06, following CED. The 
CED experiment was conducted 14 days after the inoculation. Here we confirmed that BPN-C8 
can transfect the tumor core in both xenografts model (Figure 3.9).  Thus, further validation will 
be needed to confirm therapeutic efficacy when widespread transgene expression of a tumor-
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Figure 3.9: Transgene expression mediated by CED of BPN-C8 carrying ZsGreen-expressing 
plasmids in CHLA-06- and BT37-based orthotopic human xenografts tumor tissues. 
Representative images depicting volumetric distribution of reporter transgene expression (green) in 
orthotopic brain tumors (DAPI, blue). Scale bar = 500 µm.  
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3.6 Transgene expression mediated by lyophilized BPN-C8 
Lyophilized PBAE nanoparticles can be stored for years without losing efficacy (14), and are 
easier to administer, as the user simply needs to add water and inject. To ensure that BPN-C8 
did not lose effectiveness after lyophilization, we compared the physicochemical properties of 
the freshly prepared and lyophilized nanoparticles and found no significant difference between 
them (Table 3.2). We also compared in vivo transgene expression of fresh versus lyophilized 
BPN-C8 and found that measurements of volumetric distribution of transgene expression 
showed no statistical difference (p > 0.05) (Figure 3.10). This demonstrates that BPN-C8 
nanoparticles can be lyophilized with no change in properties or efficacy.  
       








Volume of transgene 
expression 
 SEM (mm3)
Fresh 60 ± 7 0.09 3.5 ± 4.1 7.2 ± 0.4
Lyophilized 64 ± 4 0.13 4.9 ± 5.5 7.3 ± 0.7
Table 3.2: Physicochemical properties of fresh and lyophilized BPN-C8. 
a 
Hydrodynamic diameter and polydispersity index (PDI) were measured by dynamic 
light scattering (DLS) in ultrapure water. Mean ± SEM (n ≥ 3).  
b 
ζ-potential was measured by laser Doppler anemometry in 10mM NaCl at pH 7.0. 
Mean ± SEM (n ≥ 3).  




































Figure 3.10: Transgene expression mediated by CED of lyophilized BPN-C8 carrying 
ZsGreen-expressing plasmids in healthy mice brain tissues. (A) Representative Z-stacked 
confocal images and (B) Isosurface 3D images depicting volumetric distribution of reporter 
transgene expression (green) in healthy mouse brains, obtained by stacking multiple sequential 
confocal images 48 hours after the treatment. Scale bar = 1 mm. (B) Comparative volume of 
transgene expression mediated by CED of fresh and lyophilized BPN-C8 (n ≥ 4 mice). 




Here we established a series of eight leading PBAE polymers, with similar chemical 
structure, previously shown to provide efficient in vitro gene transfer in 2D cell culture. These 
polymer variants have never been tested as BPN formulations for widespread gene transfer in 
the brain following intracranial infusion by CED. Although we did not compare the structure-
function relationship of the various candidates in this study, we saw that the small differences in 
the chemical structure of the end-capping groups led to significant changes in colloidal stability, 
varying their performance in 3D culture and in vivo. As a result, we discover a better BPN 
formulation for widespread gene transfer in healthy and tumor brain than the previously reported 
PBAE BPN. Furthermore, this new and stable BPN formulation, when combined with a cryo-
protectant, can be lyophilized without changing the physicochemical properties or effectiveness 
in vivo. This allows for reconstitution at a higher concentration, which is particularly beneficial for 
intracranial injections, in which infusion volumes are limited due to size and pressure constraints 
within the brain.  
The CED approach overcomes a major obstacle hindering the development of drug or gene 
therapies, i.e. blood-brain barrier permeability. However, as we have shown before, the CED 
technique is not enough for achieving widespread distribution and transgene expression. Based 
on our results, a balanced combination of small diameter (< 100 nm), near-neutral surface 
charge (< 6 mV), small PDI (< 0.2), and colloidal stability in physiological environments 
(diameter <100 nm and PDI < 0.3, maintained up to 4 hours) is crucial for achieving the best 
possible distribution and transfection in the brain. Furthermore, in agreement with our previous 
observations using the gold-standard polyethyleneimine (PEI) polymer (Chapter 2), we 
confirmed that the overall protein expression level is directly proportional to the volume of 
transgene expression. This indicates that more cells are getting transfected by the widespread 
distribution, not by being exposed to a higher amount of DNA nanoparticle in a localized region.   
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Blind scoring by a certified neuropathologist after nanoparticle delivery via CED is rarely 
found. Some studies report H&E staining or immunofluorescent images taken within 1 mm 
around the injection site a few days after nanoparticle administration (24, 39-41), with very few 
reporting long-term safety profiles (39, 42). Overall, except for one of our previous studies, there 
are no reported scores for hemorrhage and inflammation after intracranial nanoparticle delivery 
(24), which makes the comparison of neurotoxicity profiles more challenging. Nevertheless, in 
agreement with similar studies, we observed no severe neurotoxicity 3 days post-nanoparticle 
administration, only minimal tissue disruption and inflammation in relation to the acute injury at 
the needle track. This was comparable for all 4 study groups including sterile medical-grade 
normal saline, which confirms that the combinational approach of BPN and CED could safely 
translate into clinical trials, specifically for patients that must undergo brain surgery for tumor 
resection.  
Interestingly, some studies suggest that 2D in vitro screening for PBAE polymer-based 
nanoparticles is more suitable for comparison of transfection efficiencies than multicellular 3D 
spheroids. This is attributed to the fact that cationic nanoparticles (i.e. UPN) are primarily taken 
up by the cells in the periphery of the 3D structure, while most of the cells in the interior remain 
untransfected (43). However, we have previously shown (Chapter 2), that 3D multicellular 
spheroids, unlike 2D cell cultures, serve as an excellent in vitro model reliably predicting gene 
vector behaviors, particularly for DNA nanoparticles possessing greater surface PEG coverage 
(i.e. BPN) because it better recapitulates architecture and biology of solid tumors observed in 
vivo by simulating an ECM-filled intercellular permeability barrier (44-47). Here we confirmed 
that PBAE BPN efficiently transfect 3D tumor spheroids, with more accurate in vivo-correlation 
than 2D in vitro studies. More importantly, we clearly detected a trend with the colloidal stability 
and physicochemical properties of the eight BPN variants that facilitated the selection of the 




One of the biggest limitations for gene therapy in the brain is poor distribution of therapeutic 
transgene expression in the tumor region due to high intratumoral pressure (48) that facilitates 
outward diffusion of DNA nanoparticles from the core to the tumor edge. In this study, we 
noticed that the volume of transgene expression mediated by identically administered BPN was 
comparable in healthy brain tissue and in GL261-based orthotopic tumor. This is not readily 
expected as the high cellularity commonly found in tumors would render the intercellular spaces 
narrower, thereby potentially reinforcing the tumor ECM as a steric barrier. Furthermore, the 
ability of BPN-C8 to efficiently transfect the tumor tissue in a widespread-manner was consistent 
in all three orthotopic brain tumor models, including human xenografts for AT/RTs. However, an 
additional method to confine and sustained therapeutic transgene expression to tumor cells 
would be desired, particularly when surgery is required, and therapy can exert a toxic effect to 
normal tissues (e.g. cytotoxic genes).  
5. Conclusions 
  Here we introduce a state-of-the-art biodegradable polymer-based DNA nanoparticle 
capable of efficiently penetrating both healthy brain parenchyma and brain tumor tissue. 
Specifically, a lead formulation, BPN-C8, exhibited the greatest ability to provide widespread and 
high-level transgene expression in 3D tumor spheroids and orthotopically-established brain 
tumors compared to the other seven BPN candidates. We note that while the PBAE polymer is 
biodegradable and cannot be store for long term use in water, BPN-C8, when combined with a 
cryo-protectant, can be lyophilized without changing the physicochemical properties or 
effectiveness in vivo. To this end, our current effort focuses on achieving widespread but cancer-
selective therapeutic transgene expression via a marriage of BPN-C8 and promoters designed to 
drive transgene expression specifically in cancer cells. The non- invasiveness of delivery, the non-
immunogenicity of the BPN, and the possibility of re-dosing are all advantages that combine to 
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Widespread distribution in brain tissue via Pluronic-coated biodegradable nanoparticles 
Abstract 
Methods capable of providing safe, yet widespread drug delivery to brain cancer cells are much 
needed. It is now well established that simple diffusion-mediated dispersion of conventional 
therapeutics, including small molecule-, and protein-based drugs, do not provide widespread 
coverage throughout highly disseminated disease areas within the brain parenchyma. Given 
that malignant gliomas are characterized by such areas, it is critical to address this issue to 
deliver the therapeutic cargo to most target cells. Here we developed a nanoparticles (NPs) 
system using a most widely explored biodegradable polymer for drug delivery platforms made of 
poly(lactic-co-glycolic acid) (PLGA) blended with various Pluronic-coatings that demonstrated 
favorable colloidal stability for brain penetration after intracranial administration. After careful 
analysis of the volumetric distribution of the various Pluronic candidates in healthy rat brain 
tissue followed by convection enhanced delivery (CED), we identified the formulation with a 
dense layer of poloxamer 407, Pluronic F127 (F127/PLGA-NPs), as the lead candidate for 
efficient shielding and brain penetration. Furthermore, F127/PLGA-NPs effectively achieved 
widespread distribution in a highly aggressive orthotopic brain tumor model. Lastly, we 
successfully developed a method for cryoprotection of this formulation without compromising 
their penetrating properties and yet significantly improved brain distribution by infusing 
F127/PLGA-NPs via CED in a hyperosmolar infusate solution. This multimodal delivery strategy 
minimizes the hindrance of NPs diffusion imposed by the brain extracellular matrix and reduces 
NPs confinement within the perivascular spaces. These findings provide a strategy to overcome 






Achieving widespread distribution in the brain parenchyma is essential when it comes to the 
design of therapeutic nanoparticles (NPs) for treating brain diseases (1, 2). As previously 
discussed, NPs delivery systems used for the treatment of brain tumors is challenging due to 
the presence of multiple anatomical barriers. Furthermore, the lack of efficacy of locally 
delivered systems stem from the impaired diffusional capabilities of the chemotherapeutic 
released after infusion. This limits their application for long-term treatment regimens, further 
supporting a need for a NP platform that can penetrate within the brain and provide sustained 
release of a therapeutic.   
Surfactants are frequently used to stabilize particle emulsions, enhance drug loading, alter 
drug release, and change surface properties (3). As early as 1994, it was demonstrated that 
nanospheres, synthesized from amphiphilic copolymers composed of two biocompatible blocks 
(including PEG), exhibit dramatically increased blood circulation times and low liver 
accumulation in mice (4). Several PEG-containing block copolymers were then developed and 
among them, the amphiphilic and polymeric characters of Pluronic® block copolymers such as 
poloxamer 188 (F68), poloxamer 288 (F98), and poloxamer 407 (F127) have raised growing 
interest for the design of drug delivery systems (5) (Figure 4.1). F68 and F127 have been used 
to coat poly(lactic-co-glycolic acid) (PLGA) NPs to promote blood-brain barrier penetration (6). 
They have also been shown to improve efficacy against intracranial gliomas compared to 
uncoated particles (7-9). However, their effect on brain tissue penetration within the brain 
extracellular matrix (ECM) followed by convection-enhanced delivery (CED) is still unknown, 
particularly for F98, which has not received the same attention as F68 and F127 in scientific 
literature.  
Pluronic-coated biodegradable NPs present a potential drug delivery platform that could 
enhance treatments against diffusive brain diseases, particularly, infiltrative glioblastomas, by 
providing greater brain tissue penetration and broader therapeutic distribution in a safely 
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manner. To this end, we studied the impact of three Pluronic candidates (F68, F98, and F127), 
in relationship to their physicochemical properties favoring brain penetration followed by CED, 
using concepts and optimized procedures discussed in previous chapters. Moreover, we used 
PLGA, one of the most successfully developed biodegradable polymers for protection of drug 
from degradation, sustained release, and possibility to modify surface properties to provide 
stealthness and/or better interaction with biological materials (Figure 4.1B) (10, 11). We then 
compared the volumetric distribution of the three types of Pluronic-coated PLGA NPs in 
relationship to their size and charge, to select the lead NP formulation for further CED 
optimization and tumor studies.  
 
2. Materials and Methods 
2.1 PLGA labeling with a fluorescence dye 
PLGA polymer (carboxyl terminated, 50:50 monomer ratio) (Resomer RG 503-H, MW: 
30,500) was purchased from Evonik Industries (Darmstadt, Germany) and conjugated with 
fluorescein cadaverine dye (λEx/λEm: 493/517 nm) (Biotium, Fremont, CA). The reaction was 
carried out by carbodiimide conjugation, activating carboxyl groups from PLGA for direct 
reaction with the primary amine via amide bond formation (Figure 4.2).  Briefly, PLGA polymer 
was dissolved in dimethylformamide (DMF) and activated by N', N-di-cyclohexyl carbodiimide 
Figure 4.1: (A) Pluronic block copolymers (also known as “poloxamers”), consist of hydrophilic poly(ethylene 
oxide) (PEO) and hydrophobic poly(propylene oxide) (PPO) blocks arranged in X-Y-X tri-block structure: PEO-
PPO-PEO. Reproduced by Gottschalck and McEwen, 2004. (B) Biodegradability of PLGA based on the 
hydrolysis of the copolymer to generate the monomers, lactic and glycolic acid, which are metabolized by the 
body via the Krebs cycle. Reproduced by Nanovex Biotech Inc.  
A                                        B                                                       
poly(lactic-co-glycolic acid) 
            Biodegradable                                                               
Lactic acid         Glycolic acid 
Metabolized by the body 
hydrophilic   hydrophobic   hydrophilic 
PEO          PPO           PEO 
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(DCC) and N-hydroxysulfosuccinimide (NHS). The reaction was carried out for 3 hours under 
constant stirring at room temperature and controlled vacuum with inert N2 gas. Then, pH was 
adjusted to 7.5 and the fluorescein cadaverine dye was dissolved in DMF and added 
immediately to the activated polymer solution to react at a polymer:dye molar ratio of 1:1.2, 
respectively.  This reaction was carried out overnight under constant stirring at room 
temperature and protected from light. Next, DMF was added to dissolve the precipitates and the 
solution was filtered by gravity using a Pasteur pipette. Then, the solution was dialyzed for 3 
hours against DMF using a Spectra/Por® 6 Standard RC 1kD dialysis membrane (Spectrum 
Laboratories, Inc., Rancho Dominguez, CA). Lastly, DMF was evaporated using a Biotage® V-
10 Touch evaporation system (Biotage, Charlotte, NC) and dye conjugation was confirmed by 
nuclear magnetic resonance (NMR) analysis.  
          
2.2 Nanoparticle formulation in ultrapure water 
Organic solvents used for preparing polymer solution are known to affect the size of PLGA 
NPs synthesized through emulsion procedures (12). Partially water-miscible organic solvents—
such as benzyl alcohol, butyl lactate, and ethyl acetate—allow nanoparticle formulation through 
an emulsion-diffusion mechanism and can produce smaller nanoparticles than water-immiscible 
 #1 #2 #3 #4 
MW 30,500 719.6 206.33 11 
Amount 200 mg 5.66 mg 2.6 mg 1.5 mg 
mmols 0.0065 0.0078   
     
 Eq 1 Eq 1.2 Eq 2 Eq 2 
 
HO-polymer-COOH #1           Dye-NH2 #2               HO-polymer-CO-NH-Dye 
                                          DCC #3, NHS #4                           
Figure 4.2: Reaction scheme for polymer-dye conjugation.  
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solvents such as dichloromethane (DCM). Furthermore, Saltzman et al. reported that replacing 
DCM with ethyl acetate and using the double-emulsion technique improved the yield of small 
nanoparticles (< 100 nm in diameter) (13).  
We adapted this protocol to formulate uncoated PLGA NPs by double-emulsion method 
(Figure 4.3). Briefly, fluorescently labeled PLGA polymer was dissolved in acetonitrile (ACN) at 
30 mg/ml and 500 µL of the polymer solution was added dropwise into 2 mL of ultrapure water 
using an SGE syringe (Supelco Inc., Bellefonte, PA). The solution was stirred for 1 hour at room 
temperature for the primary emulsion, where nanoparticles were formed spontaneously. Then, 
the emulsion was poured into a beaker with 10 mL of ultrapure water to allow the secondary 
emulsion to form. This was followed by an additional 4 hours of stirring to allow the solvent to 
evaporate and particles to harden. After solvent evaporation, the particle solution was washed 
once with 1 volume of ultrapure water and collected using Amicon Ultra Centrifugal Filters 
(100,000 MWCO; Millipore Corp., Billerica, MA) at 4,000 x g for 12 minutes until final volume in 
the filter unit was 500 µL.  
                    
PLGA in ACN
stirring 1 hour








Figure 4.3: Schematic protocol for the formulation of PLGA NPs.  
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2.3 Nanoparticle formulation in F68, F98, and F127 aqueous solution 
Similarly, fluorescently labeled PLGA polymer was dissolved in ACN at 30 mg/ml and 500 
µL of the polymer solution was added dropwise into 2 mL of 1% F68, 1% F98, or 1% F127 
aqueous solution, using an SGE syringe. The solution was stirred for 1 hour at room 
temperature for the primary emulsion, where nanoparticles were formed spontaneously. Then, 
the emulsion was poured into a beaker with 10 mL of 0.5% F68, 0.5% F98, or 0.5% F127 
aqueous solution to allow the secondary emulsion to form. This was followed by an additional 4 
hours of stirring to allow the solvent to evaporate and particles to harden. After solvent 
evaporation, the particle solution was washed once with 1 volume of ultrapure water and 
collected using Amicon Ultra Centrifugal Filters (100,000 MWCO; Millipore Corp., Billerica, MA) 
at 4,000 x g for 12 minutes until final volume in the filter unit was 500 µL.  
Particle diameter is directly proportional to the polymer concentration (14). Thus, the same 
protocol was used to formulate F127/PLGA-NPs of various sizes (~60 to 350 nm) by adjusting 
the PLGA starting concentration to 5, 10, 30, 50, 60, 80 mg/ml in ACN.  
       
PLGA in ACN
stirring 1 hour









Figure 4.4: Schematic protocol for the formulation of Pluronic-coated PLGA NPs.  
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2.4 Physicochemical characterization of PLGA NPs  
The hydrodynamic diameters as well as polydispersity index (PDI) and ζ-potentials of 
uncoated and Pluronic-coated PLGA NPs were measured by dynamic light scattering (DLS) and 
laser Doppler anemometry in 10 mM NaCl solution at pH 7.0, using a Nanosizer ZS90 (Malvern 
Instruments, Southborough, MA). The size and morphology of nanoparticles were also 
confirmed by transmission electron microscopy (TEM) (Hitachi H7600, Japan). Colloidal stability 
was assessed by monitoring the change in hydrodynamic diameters and PDI in artificial 
cerebrospinal fluid (aCSF) (Harvard Apparatus, Holliston, MA) at 37 °C.  
2.5 Animal studies 
We used 6-to-8-week-old female Fischer 344 rats for the assessment of the volume of 
distribution of the various PLGA NPs. Animals were treated in accordance with the guidelines 
and policies of the Johns Hopkins University Animal Care and Use Committee. Surgical 
procedures were performed using standard sterile surgical techniques. Animals were 
anesthetized using a mixture of 75 mg/kg ketamine and 7.5 mg/kg xylazine, as previously 
described (15). A midline scalp incision was made to expose the coronal and sagittal sutures 
and a burr whole was drilled 3 mm lateral to the sagittal suture and 0.5 mm posterior to the 
bregma. Following the tumor cell inoculation or PLGA NPs administration, the skin was sealed 
using biodegradable sutures (Polysorb™ Braided Absorbable Sutures 5–0) and bacitracin was 
applied. 
2.5.1 Orthotopic tumor inoculations 
      Orthotopic tumor cell inoculations were performed as previously described in Chapter 2 (15). 
Briefly, 100,000 cells of rat glioblastoma cells expressing mKate fluorescent protein (F98-
mKate), were administered in 10 µL of DMEM over 5 minutes at a depth of 3.5 mm using a 
Neuros Syringe (50 μL; Hamilton, Reno, NV) mounted on an ultra-precise small-animal 
stereotactic frame. Of note, we inoculated rat brains with a high numbers of tumor cells, relevant 
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to clinical translation (16, 17), to establish a model mimicking malignant gliomas characterized 
by rapid tumor growth rates. 
2.5.2 Intracranial administration - CED 
To assess the volume of distribution of the various PLGA NPs, fluorescently labeled NPs 
were intracranially administered via CED. Briefly, a Neuros syringe connected to a 33-gauge 
needle was filled with 20 μL of PLGA NPs solution at a polymer concentration of 15 mg/mL and 
lowered to a depth of 3.5 or 2.5 mm of a healthy or an orthotopic tumor-bearing rat brain, 
targeting the striatum or the tumor core, respectively. PLGA NPs were then infused at a rate of 
0.5 μL/min as controlled by a Chemyx Nanojet Injector Module (Chemyx, Stafford, TX).  
2.5.3 Imaging and quantification of volumetric of distribution 
Brains were harvested immediately after PLGA NPs administration and flash-frozen in 
dry-ice. Tissues were then sectioned using a Leica CM 1905 cryostat into 100 or 50 μm coronal 
slices for healthy or tumor-bearing rats at ± 3 mm of the infusion plane in striatum or until the 
tumor tissue was no longer visible, respectively. All fluorescence images were taken using an 
LSM 710 confocal microscope under 5X magnification. We carefully optimized the settings to 
avoid background fluorescence based on the microscopy of untreated control rat brains. The 
volume of distribution was quantified using a custom-made MATLAB script that subtracted 
background fluorescence by Otsu’s method of thresholding (39, 40). The area of PLGA NPs 
coverage in each slice was integrated to calculate the total volume of distribution.  
To reconstruct 3D-rendered imaginings of F127/PLGA-NPs distribution in orthotopic 
tumor, we stacked and aligned the acquired images using Metamorph ® Microscopy Automation 
& Image Analysis Software (Molecular Devices, CA). Finally, we used an Imaris Software 






2.5.4 Histological analysis and safety profile 
Animals were sacrificed 3 days following administration and the harvested brains were fixed 
in 4% formaldehyde, processed, sectioned and stained with hematoxylin and eosin (H&E) by 
the Johns Hopkins Reference Histology Laboratory. The point of infusion was identified by the 
tissue cavity imparted by the needle and the region immediately adjacent was imaged and 
evaluated. Blind histopathological analysis was performed by a board-certified neuropathologist 
and tissues were scored from 0–3 for indications of inflammation and hemorrhage (0: no 
inflammation/hemorrhage, 1: mild, 2: moderate, 3: severe). 
2.6 Lyophilization and administration of the “ready-to-use” F127/PLGA NPs 
For lyophilized F127/PLGA-NPs formation and evaluation, NPs were initially formed as 
described above at two different PLGA concentrations, 5 and 30 mg/ml. Subsequently, sucrose 
(OPS Diagnostics, Lebanon, NJ) was added as a cryoprotectant to a final concentration of 30 
mg/mL, diluting the solution of F127/PLGA-NPs by 2-fold. Particles were then frozen in dry-ice 
and lyophilized overnight. Lyophilized F127/PLGA-NPs were stored at -20 °C until use and then 
reconstituted in sterile ultrapure water and used at the same concentration as freshly prepared 
F127/PLGA-NPs.  
To assess the effect of osmolality of infusate solutions on the distribution of the “ready-to-
use” F127/PLGA-NPs in the brain parenchyma, the osmotic pressures were adjusted by 
addition of NaCl to a final osmolality of 300 mOsm/kg, 370 mOsm/kg, and 480 mOsm/kg and 
intracranially administered via CED. The CED and imaging procedure were executed as 
described above.    
2.7 Statistical Analysis 
Statistical analysis between two groups was conducted using a two-tailed Student's t-test 
assuming unequal variances. If multiple comparisons were involved, one-way analysis of 
variance (ANOVA), followed by Sidak's multiple comparisons test, was employed, using 
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GraphPad Software (GraphPad Software Inc., La Jolla, CA). Differences were determined to be 
statistically significant at p < 0.05. Values are presented as mean ± standard error of the mean 
(SEM). 
3. Results 
3.1. Physicochemical characterization of PLGA NPs 
We formulated Pluronic-coated PLGA NPs by double-emulsion method, mixing the organic 
PLGA solution into various aqueous Pluronic solutions, F68, F98, and F127. The uncoated 
PLGA NPs were formed in ultrapure water as a negative control. Hydrodynamic diameter and 
PDI were measured by DLS in 10 mM NaCl. The ζ-potential was measured by laser Doppler 
anemometry in 10mM NaCl at pH 7.0. At least 3 independent experiments were performed for 
this analysis. Table 4.1 shows that all Pluronic-coated PLGA NPs possessed a hydrodynamic 
diameter of ~130 nm and a low PDI ~0.1, whereas uncoated PLGA NPs possessed a slightly 
larger hydrodynamic diameter of ~140 nm and higher PDI of ~0.18. On the other hand, the 
surface charge showed a trend from highly negative to near neutral, as indicated by the ζ-
potential, in the following order: uncoated > F68 > F98 > F127: -50 ± 9 , -26 ± 3 , -9 ± 3 , -4 ± 3 
mV , respectively (Figure 4.5). The particle morphology was confirmed by TEM to be ~150 nm 
spheres regardless of type of coating (Figure 4.5C), consistent with the measured 
hydrodynamic diameters (Table 4.1). 
Lastly, we assessed the hydrodynamic diameters of the various PLGA NPs following a 12-
hour incubation in aCSF at 37⁰C to predict potential alteration of particle properties in the 
physiological brain environment. We found all formulations retained their hydrodynamic 
diameters and PDI in aCSF. Notably, F98 showed less colloidal stability than the other groups, 
but even with the drastic and sudden changes, it retained the diameter in similar range as the 














Uncoated 180 ± 8 140 ± 6 0.18  -50  ± 9
F68 158 ± 2 126 ± 3 0.09 -26 ± 3
F98 162 ± 5 128 ± 4 0.12 -9 ± 3
F127 161 ± 1 134 ± 3 0.07 -4 ± 3
Table 4.1: Physicochemical properties of PLGA NPs with various Pluronic 
coatings. 
a 
Hydrodynamic diameter and polydispersity index (PDI) were measured by dynamic light 
scattering (DLS) in 10 mM NaCl at pH 7.0. Mean ± SEM (n ≥ 3).  
b 
ζ-potential was measured by laser Doppler anemometry in 10 mM NaCl at pH 7.0. Mean 
± SEM (n ≥ 3).  















































Figure 4.5. Physicochemical properties of various PLGA NPs. (A) Hydrodynamic diameters of 
30 mg/ml PLGA NPs were measured by DLS in 10 mM NaCl at pH 7.0. Mean ± SEM (n ≥ 3). (B) ζ-
potential was measured by laser doppler anemometry in 10 mM NaCl at pH 7.0. Mean ± SEM (n ≥ 
3). (C) Transmission electron microscopy images of PLGA NPs coated with F127, F98, F68, and 
uncoated when freshly made in ultrapure water. Scale bar = 800 nm.  
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Figure 4.6: Colloidal stability over 12 hours in aCSF at 37°C measured by DLS.   
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3.2. Volume of distribution in healthy rat brains 
The various PLGA NPs were administered into the rats striatum via CED, which, as 
previously described, has been clinically applied to enhance the therapeutic distribution within 
brain by creating a continuous pressure-driven bulk flow (18, 19). The volume of distribution was 
then assessed immediately after the treatment. The representative images showing the coronal 
plane at the site of administration revealed enhanced volumes of distribution for all Pluronic-
coated PLGA NPs, whereas the uncoated control was confined around the needle track (Figure 
4.7A). The trend seen in the volume of distribution of PLGA NPs in rat brains was inversely 
correlated to their surface charge: F127 > F98 > F68 > uncoated. Quantitively, F127/PLGA-NPs 
exhibited significantly greater volumetric distribution compared to all the groups (Figure 4.7B), 
with an average volumetric distribution of 38 ± 5 mm3, 23 ± 3 mm3, 13 ± 0.7 mm3, 4 ± 0.7 mm3, 
for F127, F98 (p <0.05), F68 (p < 0.001), uncoated (p < 0.001), respectively. Notably, 
F98/PLGA-NPs showed the second highest value for volume of distribution, exhibiting statistical 
significance when compared to F68 (p < 0.05) and uncoated (p < 0.01) NPs.  
       
We also confirmed that the two best Pluronic candidates, F98 and F127, were still present 
in the brain parenchyma after 48 hours from NPs treatment, albeit, the volume of distribution 































Figure 4.7: Volume of distribution mediated by CED of various PLGA NPs in healthy rat 
brain tissues. (A) Representative 2D images depicting volumetric distribution at the infusion site 
of PLGA NPs when uncoated, and coated with F68, F98, and F127 in healthy rat brains, obtained 
by confocal microscopy immediately after NPs treatment. Sale bar = 1 mm. (B) Quantification of 
the volume of distribution of PLGA NPs (n ≥ 4 rats). Differences are statistically significant as 
indicated (*p < 0.05, **p < 0.01, ***p < 0.001).  




decreased by ~2-fold when compared to the volume of distribution achieved immediately after 
CED. Quantitively, F98 showed a volumetric distribution of 10 ± 2 mm3, whereas F127 
demonstrated significantly greater distribution than F98 by ~2-fold, with 22 ± 3 mm3 (p < 0.05).  
         
3.3. Effect of polymer concentration on F127/PLGA-NPs 
Next, we evaluated the effect of PLGA concentration on the physicochemical properties of 
the F127/PLGA-NPs. The aforementioned data of the various types of PLGA NPs was taken 
from batches at a starting polymer concentration of 30 mg/ml. This same protocol was then 
adjusted to formulate F127/PLGA-NPs of various sizes (~60 to 350 nm) by changing the PLGA 
starting concentration to 5, 10, 30, 50, 60, 80 mg/ml. Here, the batch of F127/PLGA-NPs at a 
starting concentration of 30 mg/ml was used as a control. The highest polymer concentration 
that provided consistent NPs yield, according to DLS, was 80 mg/ml; concentrations greater 
than that one did not allow successful recovery during the washing process due to significant 
polymer aggregation (data not shown).  
Table 4.2 shows a tendency consistent with the expected results, where increments of the 
starting PLGA concentration yielded larger diameters. Although the PDI was not significantly 
affected by the polymer concentration, the surface charge showed a “more negative” inclination 
as the PLGA concentration increased. Note, we named each condition based on the 


























Figure 4.8: Volume of distribution of F98/PLGA-NPs and F127/PLGA-NPs 48 hours after 
CED. (A) Representative 2D images depicting volumetric distribution at the infusion site in 
healthy rat brains, obtained by confocal microscopy 48 hours after NPs treatment. Sale bar = 
1 mm. (B) Quantification of the volume of distribution of F98/PLGA-NPs and F127/PLGA-NPs 
(n ≥ 3 rats) (t-test, *p < 0.05).  
F98                               F127 A                                B 
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hydrodynamic diameter after the number mean reported by DLS. For example, “F127/PLGA-
130” refers to the control batch of 30 mg/ml, which showed a hydrodynamic diameter of 135 ± 5 
nm. Lastly, we assessed the colloidal stability of the various F127/PLGA-NPs (only four are 
shown in Figure 4.9) and confirmed that the hydrodynamic diameters did not change over time 
in physiological conditions.  
       
     
3.4. Effect of changes in diameter on in vivo volume of distribution  
As discussed in previous chapters, cationic polymer-based NPs have a “sticky” limitation 
when it comes to brain penetration, which is due to the adhesive moieties of brain ECM and 












F127/PLGA-60 5 89 ± 2 63 ± 3 0.07 ± 0.05  -1.6  ± 6.2
F127/PLGA-100 10 111 ± 8 89 ± 8 0.08 ± 0.04 -2.2 ± 5.8
F127/PLGA-130 30 160 ± 7 135 ± 5 0.08 ± 0.03 -3.5 ± 4.5
F127/PLGA-170 50 198 ± 9 171 ± 13 0.10 ± 0.02 -4.0 ± 4.2
F127/PLGA-200 60 257 ± 1 198 ± 4 0.16 ± 0.02 -4.6 ± 4.3
F127/PLGA-350 80 387 ± 14 341 ± 36 0.10 ± 0.04 -4.8 ± 4.1
Table 4.2: Effect of polymer concentration on physiochemical properties of F127/PLGA-NPs. 
a 
Hydrodynamic diameter and PDI were measured by DLS in 10 mM NaCl ± SEM (n ≥ 3).  
b 
ζ-potential was measured by laser Doppler anemometry in 10 mM NaCl. Mean ± SEM (n ≥ 3).  





























5 0  m g /m l
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1 0  m g /m l
Figure 4.9: Effect of polymer concentration in colloidal stability of F127/PLGA-NPs. Colloidal 
stability over 12 hours in aCSF at 37°C measured by DLS. 
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efficiently diffuse in ex vivo and in vivo brain tissue even after PEGylation (20). To this end, we 
evaluated whether F127/PLGA-NPs possessing large diameters and a near neutral, yet slightly 
negative, surface charge can still achieve widespread distribution when combined with the CED 
technique. For this study we selected four of the six groups from Table 4.2, F127/PLGA-60, 130, 
170, and 200 nm.  
Figure 4.10 establishes that the widespread distribution is inversely correlated with the 
hydrodynamic diameter. Quantitively, there was no significant difference between the particles 
in the smaller range, 60 nm and 130 nm, showing 40 ± 4 mm3 and 38 ± 5 mm3, for the volume 
of distribution, respectively. Similarly, the particles in the larger range, 170 nm and 200 nm, 
achieved comparable distribution, showing 25 ± 5 mm3 and 24 ± 3 mm3, respectively.  Both, 60 
and 130 nm NPs demonstrated statistical significance when compared to 200 nm NPs (p < 
0.05) but not against 170 nm NPs.  
 
3.5. Histopathological analysis and safety profile 
To demonstrate the safety of Pluronic-coated PLGA NPs followed by intracranial 
administration via CED, we compared the toxicity of F98/PLGA NPs and F127/PLGA NPs to 




















































60    130    170     200 
Hydrodynamic diameter (nm)   
Figure 4.10: Volume of distribution mediated by CED of different sizes of F127/PLGA-NPs 
in healthy rat brain tissues. (A) Representative 2D images depicting volumetric distribution at 
the infusion site in healthy rat brains, obtained by confocal microscopy immediately after NPs 
treatment. Sale bar = 1 mm. (B) Quantification of the volume of distribution of the various 
F127/PLGA-NPs (n ≥ 4 rats) (t-test *p < 0.05).   
A                                             B                             60 nm 




days from the NPs administration, the average toxicity scores of the brain tissues for both 
Pluronic coatings were comparable to those of NS-treated controls (Figure 4.11), with an 
average score of ~1.5-2 for hemorrhage and inflammation, suggesting that they were well-
tolerated at the dose administered (15 mg/mL, 20 μL). Notably, the inflammation score 
increased with the respective volume of distribution in the brain (F127 > F98). Importantly, 
regardless of the type of particle, inflammatory and hemorrhagic changes were confined around 
the injection site and did not propagate throughout the brain tissue. All hemorrhage and 
inflammation scores were negligible, ~0-1, after 30 days (data not shown).  
 
3.6. Widespread distribution in orthotopic brain tumors 
We next evaluated whether F127/PLGA-NPs can effectively diffuse and penetrate the 
dense cellularity within an orthotopic model of aggressive brain tumor following CED. The model 
was established by intracranial stereotactic inoculation of 1 x 105 F98 cells and a CED 
experiment was conducted 10 days after the inoculation when a large volume (~50 mm3) of 
orthotopic tumor was established in the rat striatum. As shown by representative 3D-
reconstructed images, F127/PLGA-NPs exhibited almost 100% tumor coverage, with 










In flam m ation
H e m o rrh a g e
Figure 4.11: Histopathological analysis and safety profile of F98/PLGA-NPs and F127/PLGA-NPs 
following CED administration. (A) Representative images of the injection site with hematoxylin and 
eosin staining in healthy brain tissue 3 days after CED at 20X (top, scale bar = 500 µm) and 200X 
(bottom, scale bar = 100 µm) magnitude. Normal saline was used as a control. (B) Inflammation and 
hemorrhage were scored by a board-certified neuropathologist using a custom scale (0: no 
inflammation/hemorrhage, 1: mild, 2: moderate, 3: severe). 
NS                          F127                          F98 
A                                                                     B 
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widespread distribution inside and outside the tumor core (Figure 4.12). Highly invasive tumor 
cells that migrate beyond the tumor edge and infiltrate into normal brain tissue are responsible 
for recurrence of malignant gliomas (21). Thus, the unique ability of F127/PLGA-NPs to 
efficiently penetrate both normal brain parenchyma and brain tumor tissue may serve favorably 
for this specific application. 
     
3.7. Lyophilization and cryoprotection of F127/PLGA-NPs 
Pluronic-coated PLGA NPs are stable at room temperature in aqueous solution, therefore, 
they can retain their colloidal stability for weeks and even months (Table 4.3). However, without 
proper care, the polymer concentration can be affected over time due to water evaporation, 
which could lead to “gel-like” consistency. Therefore, lyophilized NPs are more convenient for 





Figure 4.12:  Volume of distribution mediated by CED of F127/PLGA-NPs in F98-mKate 
rat tumor brain tissues. Representative 3D-rendered images depicting volumetric 
distribution of F127/PLGA-NPs (green, outlined by short-green-dashed lines) in orthotopic 
F98-mKate brain tumors (light gray, outlined by long-red-dashed lines), obtained by stacking 
multiple sequential confocal images. Top panel shows overlap between F127/PLGA-NPs and 
tumor bulk. Bottom panel shows areas where F127/PLGA-NPs are surrounding the tumor. 
Scale bar = 2 mm.  
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inject. To ensure that F127/PLGA-NPs do not lose their nanoparticle characteristics after 
lyophilization, we compared the physicochemical properties of two different types of F127-
coated NPs, 60 nm and 130 nm, with and without sucrose as a cryoprotectant. As Table 4.4 
shows, particles without sucrose do not retain the original size and charge, whereas particles 


















172 ± 5 131 ± 5 0.13 -8 ± 4
F127/PLGA-130
(1 month)
170 ± 6 129 ± 2 0.11 -4 ± 3
Table 4.3: Physiochemical properties of Pluronic-coated PLGA NPs after a month. 
a 
Hydrodynamic diameter and PDI were measured by DLS in 10 mM NaCl ± SEM (n ≥ 3).  
b 
ζ-potential was measured by laser Doppler anemometry in 10 mM NaCl at pH 7.0. 











124 ± 3 93 ± 2 0.14 ± 0.03  -3.7  ± 8.8
F127/PLGA-60
(with sucrose)
93 ± 5 52 ± 4 0.17 ± 0.04 -1.9 ± 6.9
F127/PLGA-130
(no sucrose)
549 ± 135 180 ± 97 0.49 ± 0.12 -4.5 ± 3.5
F127/PLGA-130
(with sucrose)
170 ± 6 127 ± 2 0.10 ± 0.02 -5.3 ± 5.1
Table 4.4: Physiochemical properties of F127/PLGA-NPs after lyophilization. 
a 
Hydrodynamic diameter and PDI were measured by DLS in 10 mM NaCl ± SEM (n ≥ 3).  
b 
ζ-potential was measured by laser Doppler anemometry in 10 mM NaCl at pH 7.0. 
 Mean ± SEM (n ≥ 3).  
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3.8. Effect of osmolality on in vivo volume of distribution  
Prior studies have demonstrated that administration of hyperosmolar saline in brain tissue 
results in enlargement of the ECM mesh spacings as water is drawn out of cells into intercellular 
space via an osmotic gradient established by the hyperosmolar saline (22-24).To verify that the 
osmotic modulation of the intercellular space translates in vivo, we administered lyophilized 
F127/PLGA-NPs via CED in saline-based infusate solutions with varying osmolality and 
determined their effects on the volume of distribution. Fresh particles were infused at 300 
mOsm/kg (iso-osmolar, 0.9 % saline) as a control, yielding 41 ± 4 mm3. We discovered that the 
volume of distribution was positively correlated with the osmolality of the infusate solution 
(Figure 4.13). Quantitively, NPs infused at 480 mOsm/kg (hyper-osmolar) exhibited significantly 
greater volume of distribution, showing 69 ± 6 mm3, compared to 370 and 300 mOsm/kg, which 
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Figure 4.13: Volume of distribution of lyophilized F127/PLGA-NPs in healthy rat brain tissues at 
various osmotic pressures. (A) Representative 2D images depicting volumetric distribution at the 
infusion site of lyophilized F127/PLGA-NPs in healthy rat brains at various osmotic pressures: 480 
mOsm/kg, 370 mOsm/kg, and 300 mOsm/kg, obtained by confocal microscopy immediately after NPs 
treatment. Sale bar = 1 mm. (B) Quantification of the volume of distribution of lyophilized F127/PLGA-
NPs (n ≥ 3 rats). Differences are statistically significant as indicated (* p < 0.05, **p < 0.01).  
480 mOsm/kg         370 mOsm/kg        300 mOsm/kg 




Pluronic-coating enhances NPs physicochemical properties for brain penetration, including 
colloidal stability and near-neutral surface charge. The size and charge can be manipulated as 
necessary by adjusting the starting PLGA concentration but keeping into consideration that the 
volumetric distribution is inversely correlated to the hydrodynamic diameter, without altering the 
colloidal stability. This demonstrates that the “mesh-like” pores sizes of the brain tolerate for a 
dynamic equilibrium when slow pressure gradients occur, which allow “expansion” and 
“flexibility” for enough penetration when larger, but well coated, NPs are infused via CED. 
F127/PLGA-NPs provided the highest volume of distribution in healthy brain parenchyma, with 
great particle retention after 48 hours from CED. We also confirmed that this new design, 
F127/PLGA-NPs, can efficaciously achieved widespread distribution into a highly aggressive 
orthotopic brain tumor model when combined with CED, becoming the lead Pluronic-coated 
formulation for our further NPs studies, utilizing chemotherapeutics for brain tumors (next 
Chapter). Lastly, we sought to alter the pore sizes of the rat brain ECM by using lyophilized NPs 
with infusate solutions of varying osmolality, which improved the volumetric distribution in vivo. 
The combination approach of the “ready-to-use” F127/PLGA-NPs, administered in hyper-
osmolar infusate solutions via CED, may be widely employed to promote widespread delivery of 
therapeutics throughout the brain.  
As discussed in previous chapters, the CED approach overcomes a major obstacle 
hindering the development of drug therapies, i.e. poor local diffusion, by allowing slower infusion 
rates and controlled pressure gradients in the brain parenchyma. However, as we have shown 
before, the CED technique is not enough for achieving widespread distribution. Poloxamers 
such as F127, F98, and F68, consist of a hydrophobic polypropylene oxide (PPO) block and 
hydrophilic polyethylene oxide (PEO) segments, where the composition (PPO:PEO) and MW 
(block length) impact the properties of the surfactant (25).  Without Pluronic coatings, PLGA 
NPs have exposed hydrophobic regions on the particle core and ζ-potentials more negative 
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than -40 mV. These particles showed to adhere to components within the brain parenchyma by 
electrostatic or hydrophobic interactions, limiting the diffusive nature of the particles even after 
CED. Furthermore, we confirmed that although the significant differences in the surface charge 
of the various types of PLGA NPs do not affect the colloidal stability under physiological 
conditions, widespread distribution remains inversely correlated with the ζ-potentials. Since 
F127 has a longer PPO segment compared to F98 and F68 (5), it allowed better shielding of 
any exposed hydrophobic regions. Consequently, F127 demonstrated better volumetric 
distribution in healthy brain tissues than F98, F68, and uncoated PLGA NPs, respectively.  
The pore sizes of the brain ECM has been previously estimated to be ~38 - 64 nm (26), but 
we have recently re-evaluated them using non-adhesive probes to be as large as ~110 nm (20). 
Therefore, there seems to stand a “myth” about the size-threshold for brain tissue penetration to 
be less than 100 nm. However, a lot of studies have combined the CED approach with 
nanocarriers possessing ~100 - 150 nm in size to treat brain tumors (27). Very few studies have 
used the CED technique to infuse nanocarriers with larger diameters, probably due to the 
known size-constraint in the ECM. As an example, MacKay J. A. et al. reported that ~200 nm 
liposomes penetrated less than 80 nm liposomes even when shielded with PEG (28). Similarly, 
Zhan W. et al. reported that liposomes with 100 nm and 135 nm in diameter have comparable 
diffusivity in tumor tissue, whereas the value reduces by one order of magnitude when diameter 
reaches 500 nm (29). This is consistent with what we saw when infusing F127/PLGA-NPs with 
diameters larger than ~160 nm, which experienced a reduction in the volumetric distribution by 
~2-fold after CED. Based on these results, we determined that non-adhesive NPs, smaller than 
~150 nm, are preferable for maximum brain tissue penetration, particularly for brain tumor 
applications.  
The unique pathological hallmarks of brain tumors, particularly malignant gliomas, present 
significant challenges for CED. First, brain tumors are often characterized by the presence of 
necrotic regions, hemorrhage and fibrin clots, making them naturally heterogeneous structures  
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(30). Second, the increased vascular permeability in tumors and surrounding regions can cause 
rapid clearance of infused drugs (27). Additionally, the high pressure within brain tumors can 
lead to reflux or backflow of the infusate up through the catheter (18). These features have 
shown to affect distribution of polymer-based NPs after CED. Therefore, nanoparticle 
distribution depends on the size and properties of the tumor and appears to be heterogeneous 
and asymmetric (31). Saucier-Sawyer J. K. et al. showed how significant quantities of PLGA 
NPs tend to accumulate in the peritumoral space, such that most of the tumor is surrounded by 
particles which are distributed along the tumor margins. In our studies, images from 
F127/PLGA-NPs infused into large F98 tumors showed consistent coverage of the tumor, where 
the margins of these larger tumors are surrounded by the “excess” of particles that diffused 
further away from the tumor core due to the “human-error” of the CED execution. These findings 
suggest that tumor size and NPs characteristics are important criteria that should be considered 
when determining infusion site and parameters for CED.  
The steric obstruction imposed by the ECM structure remains a challenging limitation to non-
adhesive NPs for achieving widespread distribution in the brain (32), particularly when relatively 
large NPs are required. To overcome this hurdle, Nicholson et al. and Zhang C. et al. have 
demonstrated that exposure of brain tissues to modestly hyperosmolar solutions (500 
mOsmol/kg) increases the volume of the intercellular space, which minimizes the tissue's 
resistance to NP diffusion (23, 24). In agreement with these studies, we demonstrated that the 
osmotic modulation of the “ready-to-use” F127/PLGA-NPs resulted in enhanced volume of 
distribution, by enlargement of the ECM mesh spacings as water is drawn out of cells into 







In this study, we showed the use of Pluronic coatings to improve the ability of the most-
widely used biodegradable PLGA nanoparticle platform to penetrate within the brain 
parenchyma. This led to the discovery of a new brain-penetrating nanoparticle formulation, 
F127/PLGA-NPs, for future drug studies in brain tumors. We also developed a simple and safe 
method to maximize the distribution of therapeutic F127/PLGA-NPs in the brain, combining the 
CED approach in a hyperosmolar infusate solution, that could address major drawbacks 
currently associated with CED applications in clinical trials, including limited ECM distribution 
and perivascular sequestration. Additional studies need to be completed to optimize and 
determine drug-loading and release dependence on formulation parameters to obtain a 
nanoparticle platform that can penetrate to infiltrative tumor cells and deliver a sustained, 
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